etidronate has been researched along with Osteoporosis in 509 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 9.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 9.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| " We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis." | 9.14 | Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. ( Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN, 2009) |
| " The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment." | 9.14 | Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. ( Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P, 2010) |
| "Our results indicate that longterm (up to 7 years) intermittent cyclical etidronate therapy is safe and effective for prevention and treatment of corticosteroid-induced osteoporosis in patients with connective tissue diseases." | 9.13 | Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. ( Hirakata, M; Kaneko, Y; Katsuki, Y; Kimura, N; Kuwana, M; Sato, S; Suwa, A; Takada, T, 2008) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 9.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| " A randomised study was performed to determine whether treatment with cyclical etidronate and/or calcium for 5 years prevents fractures or reverses/reduces bone loss in patients receiving glucocorticoid treatment for asthma." | 9.11 | Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. ( Campbell, IA; Douglas, JG; Francis, RM; Prescott, RJ; Reid, DM, 2004) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 9.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan." | 9.10 | A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002) |
| "These results indicate that intermittent cyclical etidronate therapy is effective for the prevention and treatment of corticosteroid induced osteoporosis in patients with connective tissue diseases." | 9.10 | Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. ( Fujii, T; Hirakata, M; Kuwana, M; Mimori, T; Nakamura, K; Nojima, T; Ohosone, Y; Sato, S; Suwa, A; Yasuoka, H, 2003) |
| "Etidronate treatment administered for 36 months reversed lumbar spine bone loss, and appeared to be safe in patients with established corticosteroid induced osteoporosis." | 9.09 | 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. ( Adachi, JD; Bensen, WG; Bianchi, F; Cividino, A; Goldsmith, CH; Gordon, M; Ioannidis, G; Kaminska, E; Petrie, A; Scocchia, T; Sebaldt, RJ; Stephenson, GF, 1999) |
| "Cyclical etidronate administered with supplemental calcium did not significantly improve bone density in patients with primary biliary cirrhosis." | 9.09 | Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. ( Dickson, ER; Jorgensen, RA; Khosla, S; Lindor, KD; Tiegs, RD, 2000) |
| "To compare the bone-mass effects of calcium supplementation and intermittent cyclic etidronate in patients with established corticosteroid-induced osteoporosis." | 9.08 | Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. ( Mulder, H; Snelder, AA; Struys, A, 1995) |
| "Twelve primary biliary cirrhosis patients (all Child-Pugh Class A), treated with prednisone in the context of a 1-year placebo-controlled pilot study with prednisone (maintenance dose 10 mg daily), and azathioprine (50 mg daily), were randomized to receive either cyclical etidronate (400 mg daily, during 2 weeks) alternated with calcium 500 mg daily during 11 weeks or calcium alone." | 9.08 | Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. ( den Ouden, JW; Hop, WC; Pols, HA; Schalm, SW; van Buuren, HR; van Leeuwen, JP; Wolfhagen, FH, 1997) |
| "To investigate whether administration of sodium fluoride (NaF) in addition to cyclical etidronate has a positive effect on bone mineral density (BMD) in patients with established osteoporosis during continued treatment with corticosteroids." | 9.08 | Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? ( Bijlsma, JW; Gerrits, MI; Haanen, HC; Houben, HH; Jacobs, JW; Lems, WF; van Rijn, HJ; van Veen, GJ, 1997) |
| "An open study over 4 yr has been conducted to determine the efficacy of cyclical etidronate treatment in patients from the community, with osteoporosis and in those at risk who attended an osteoporosis clinic; and to clarify whether bone remodelling returns to baseline values and bone mass is maintained after completion of a 3 yr course of treatment." | 9.08 | The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment. ( Fairney, A; Kyd, P; Thomas, E; Wilson, J, 1998) |
| "Clinical experience with cyclical etidronate for the treatment of osteoporosis was reviewed in 69 consecutive patients." | 9.07 | Clinical experience with etidronate in osteoporosis. ( Fogelman, I; Ryan, PJ, 1994) |
| "A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover." | 9.06 | Effect of etidronate disodium on bone turnover following surgical menopause. ( Bevan, J; Fogelman, I; Hart, DM; Leggate, I; Scott, E; Smith, ML, 1989) |
| "Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan." | 8.84 | [Evidence and utility of etidronate for the treatment of osteoporosis]. ( Iba, K; Takada, J; Yamashita, T; Yoshizaki, T, 2008) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 8.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 8.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 8.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 7.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "To compare the bone-mass effects of intermittent cyclic etidronate administration in patients of various rheumatic disease patients with corticosteroid-induced osteoporosis." | 7.71 | [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis]. ( Koshiba, M; Kumagai, S; Maekawa, S; Morinobu, A; Morinobu, S; Nakamura, T; Sugimoto, T; Yamauchi, M, 2002) |
| "In an open prospective study, we evaluated differences between patients with (wRVF group) and without recurrence of vertebral fracture (woRVF group) during cyclical etidronate therapy for osteoporosis." | 7.70 | Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation. ( Alexandre, C; Barou, O; Lafage-Proust, MH; Thomas, T; Vico, L, 1999) |
| "Our clinical practice has been to offer treatment with cyclical disodium etidronate and high dose calcium supplements (1500-1600 mg/day) to all female patients with osteoporosis who are unable or unwilling to take hormone replacement therapy (HRT), and male osteoporotics." | 7.69 | Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. ( Belchetz, PE; Oldroyd, B; Orme, SM; Simpson, M; Smith, MA; Stewart, SP; Westmacott, CF, 1994) |
| "The efficacy of the biphosphonate etidronate has recently been demonstrated versus the vertebral fracture rate in fractured involuted osteoporosis in the literature." | 7.68 | [Bone histomorphometric study in involuted fractured osteoporosis treated with 1-ethane-1-hydroxybiphosphonate (etidronate) during one year]. ( Alexandre, C; Chappard, D; Pallot-Prades, B; Prallet, B; Riffat, G; Tavan, P, 1991) |
| "Treatment with etidronate suppressed this increase." | 6.76 | Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy. ( Furukawa, F; Hata, M; Hattori, M; Ikeda, T; Kaminaka, C; Kanazawa, N; Nishide, T; Ohta, C; Tsujioka, K; Uede, K; Yamamoto, Y, 2011) |
| "Osteoporosis is a recognized complication of corticosteroid therapy." | 6.68 | Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. ( Adachi, JD; Bensen, WG; Brown, J; Chines, AA; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; Ste-Marie, LG; Tenenhouse, A, 1997) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | 5.36 | Intravenous zoledronic acid: what are the indications for male osteoporosis? ( Maricic, M, 2010) |
| "Kynurenine analysis was performed by HPLC." | 5.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| "Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures." | 5.29 | Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. ( Kochman, ML; Melton, ME, 1994) |
| "Osteoclastic bone resorption is activated by 7 days of oral neutral phosphate and inhibited with a brief pulse (5 days) of etidronate disodium at a high dose (20 mg/kg body weight)." | 5.28 | Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. ( LeBlanc, AD; Mallette, LE; Mechanick, JI; Pool, JL, 1989) |
| " zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO)." | 5.17 | Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. ( Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G, 2013) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 5.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 5.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| " We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis." | 5.14 | Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. ( Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN, 2009) |
| " The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment." | 5.14 | Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. ( Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P, 2010) |
| "Our results indicate that longterm (up to 7 years) intermittent cyclical etidronate therapy is safe and effective for prevention and treatment of corticosteroid-induced osteoporosis in patients with connective tissue diseases." | 5.13 | Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. ( Hirakata, M; Kaneko, Y; Katsuki, Y; Kimura, N; Kuwana, M; Sato, S; Suwa, A; Takada, T, 2008) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 5.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "These findings suggest that both etidronate and calcium and vitamin D are equally efficacious for reversing the degree of osteoporosis in patients with AN." | 5.12 | The effects of bone therapy on tibial bone loss in young women with anorexia nervosa. ( Kojima, S; Muranaga, T; Nagai, N; Nakahara, T; Naruo, T; Nozoe, S; Tanaka, M, 2006) |
| "In a prospective, randomized controlled trial of previously untreated postmenopausal women with osteoporosis, oral BP therapy (daily doses of either 10 mg alendronate or 5 mg risedronate) in combination with calcium/vitamin D was compared to calcium/vitamin D treatment alone (control group)." | 5.12 | Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. ( Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V, 2006) |
| " A randomised study was performed to determine whether treatment with cyclical etidronate and/or calcium for 5 years prevents fractures or reverses/reduces bone loss in patients receiving glucocorticoid treatment for asthma." | 5.11 | Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. ( Campbell, IA; Douglas, JG; Francis, RM; Prescott, RJ; Reid, DM, 2004) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 5.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan." | 5.10 | A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002) |
| "These results indicate that intermittent cyclical etidronate therapy is effective for the prevention and treatment of corticosteroid induced osteoporosis in patients with connective tissue diseases." | 5.10 | Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. ( Fujii, T; Hirakata, M; Kuwana, M; Mimori, T; Nakamura, K; Nojima, T; Ohosone, Y; Sato, S; Suwa, A; Yasuoka, H, 2003) |
| " We used a randomized placebo-controlled design to evaluate the efficacy of one-year cyclical etidronate therapy in preventing bone loss in 83 glucocorticoid-treated patients with rheumatoid arthritis, polymyalgia rheumatica, or giant cell arteritis." | 5.09 | Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. ( Barton, I; Bonvoisin, B; Cortet, B; Hachulla, E; Roux, C, 1999) |
| "Etidronate treatment administered for 36 months reversed lumbar spine bone loss, and appeared to be safe in patients with established corticosteroid induced osteoporosis." | 5.09 | 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. ( Adachi, JD; Bensen, WG; Bianchi, F; Cividino, A; Goldsmith, CH; Gordon, M; Ioannidis, G; Kaminska, E; Petrie, A; Scocchia, T; Sebaldt, RJ; Stephenson, GF, 1999) |
| "Cyclical etidronate administered with supplemental calcium did not significantly improve bone density in patients with primary biliary cirrhosis." | 5.09 | Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. ( Dickson, ER; Jorgensen, RA; Khosla, S; Lindor, KD; Tiegs, RD, 2000) |
| " Treatments were as follows: idiopathic osteoporosis: calcium and vitamin D supplements (N = 10) or cyclical etidronate for 2 weeks followed by calcium and vitamin D supplements for 76 days (N = 29); moderate idiopathic phosphate diabetes: calcitriol and phosphate (N = 15); idiopathic hypercalciuria: hydrochlorothiazide (N = 6); and hypogonadism: testosterone (N = 3)." | 5.09 | Management of male osteoporosis. ( Catanzariti, L; Cortet, B; Delcambre, B; Grardel, B; Marchandise, X; Vasseur, J, 2001) |
| "To compare the bone-mass effects of calcium supplementation and intermittent cyclic etidronate in patients with established corticosteroid-induced osteoporosis." | 5.08 | Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. ( Mulder, H; Snelder, AA; Struys, A, 1995) |
| "Twelve primary biliary cirrhosis patients (all Child-Pugh Class A), treated with prednisone in the context of a 1-year placebo-controlled pilot study with prednisone (maintenance dose 10 mg daily), and azathioprine (50 mg daily), were randomized to receive either cyclical etidronate (400 mg daily, during 2 weeks) alternated with calcium 500 mg daily during 11 weeks or calcium alone." | 5.08 | Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. ( den Ouden, JW; Hop, WC; Pols, HA; Schalm, SW; van Buuren, HR; van Leeuwen, JP; Wolfhagen, FH, 1997) |
| " Sodium etidronate is a powerful inhibitor of bone resorption which had been proven efficacious in the prevention and treatment of postmenopausal osteoporosis." | 5.08 | Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist. ( Adami, S; Braga, V; Castello, R; Fracassi, E; Gatti, D; Rossini, M; Zamberlan, N, 1997) |
| "To investigate whether administration of sodium fluoride (NaF) in addition to cyclical etidronate has a positive effect on bone mineral density (BMD) in patients with established osteoporosis during continued treatment with corticosteroids." | 5.08 | Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? ( Bijlsma, JW; Gerrits, MI; Haanen, HC; Houben, HH; Jacobs, JW; Lems, WF; van Rijn, HJ; van Veen, GJ, 1997) |
| "An open study over 4 yr has been conducted to determine the efficacy of cyclical etidronate treatment in patients from the community, with osteoporosis and in those at risk who attended an osteoporosis clinic; and to clarify whether bone remodelling returns to baseline values and bone mass is maintained after completion of a 3 yr course of treatment." | 5.08 | The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment. ( Fairney, A; Kyd, P; Thomas, E; Wilson, J, 1998) |
| "The results show that intermittent cyclical etidronate therapy with calcium and vitamin D supplementation significantly increases lumbar spine BMD in patients with osteoporosis resulting from long-term treatment with corticosteroids." | 5.08 | A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. ( Li, F; Moniz, C; Pack, S; Pitt, P; Todd, P; Webber, D, 1998) |
| "A double blind, randomised placebo controlled study comparing cyclic etidronate and placebo during two years in 37 postmenopausal women receiving long term corticosteroid treatment, mainly for polymyalgia rheumatica (40% of the patients) and rheumatoid arthritis (30%)." | 5.08 | Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. ( Boonen, S; Dequeker, J; Geusens, P; Joly, J; Nijs, J; Raus, J; Stalmans, R; Vanhoof, J, 1998) |
| "Clinical experience with cyclical etidronate for the treatment of osteoporosis was reviewed in 69 consecutive patients." | 5.07 | Clinical experience with etidronate in osteoporosis. ( Fogelman, I; Ryan, PJ, 1994) |
| "A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover." | 5.06 | Effect of etidronate disodium on bone turnover following surgical menopause. ( Bevan, J; Fogelman, I; Hart, DM; Leggate, I; Scott, E; Smith, ML, 1989) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| " In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. ( Okazaki, R, 2009) |
| "Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan." | 4.84 | [Evidence and utility of etidronate for the treatment of osteoporosis]. ( Iba, K; Takada, J; Yamashita, T; Yoshizaki, T, 2008) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 4.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| " Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis." | 4.83 | Bisphosphonates. ( Botsis, D; Christodoulakos, G; Lambrinoudaki, I, 2006) |
| "Intermittent cyclical therapy with etidronate increases bone mineral density in spine and hip, and reduces the incidence of new vertebral fractures in women with postmenopausal osteoporosis, as well as steroid-induced osteoporosis." | 4.82 | [Etidronate]. ( Inui, K; Takaoka, K, 2003) |
| " We studied 1588 patients over the age of 50 yr who were started on cyclic etidronate (1119) or alendronate (469) in the CANDOO (Canadian Database for Osteoporosis and Osteopenia Patients) Study." | 4.82 | What predicts early fracture or bone loss on bisphosphonate therapy? ( Adachi, JD; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, R; Murray, T; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A, 2003) |
| "Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords." | 4.81 | Risedronate: a clinical review. ( Crandall, C, 2001) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 4.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "Alendronate has been approved as a first antiresorptive drug for treatment of osteoporosis in men." | 4.81 | Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. ( Ringe, JD; Rovati, LC, 2001) |
| "To conduct a pooled data analysis in a group of patients defined by sex, menopausal status, and underlying disease in order to examine the effect of intermittent cyclical etidronate in the prevention and treatment of corticosteroid induced osteoporosis." | 4.80 | A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. ( Adachi, JD; Brown, J; Cawley, MI; Cooper, C; Dequeker, J; Geusens, P; Ioannidis, G; Jenkins, EA; Laan, RF; Moniz, C; Pack, S; Pitt, PI; Roux, C; Stephenson, GF; Walker-Bone, KE, 2000) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "A 56-yr-old male developed a systemic illness while receiving cyclical oral etidronate therapy for idiopathic osteoporosis." | 4.78 | Idiopathic polymyositis complicated by arthritis and mesangial proliferative glomerulonephritis: case report and review of the literature. ( Bhalla, AK; Frost, NA; Hall, CL; Maddison, PJ; Morand, EF, 1993) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 4.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "Little is known of the effect of alendronate and risedronate on osteoporotic fractures after discontinuation of therapy." | 3.81 | Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). ( Garellick, G; Landfeldt, E; Ström, O, 2015) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| " aestivum (200 and 400 mg/kg/day, po, for 30 days) and risedronate (20 microg/kg, sc, five times a week for 30 days) following methyl prednisolone sodium succinate (10 mg/kg, sc, thrice a week for 4 weeks) induced osteoporosis in Wistar rats showed an increase in the serum levels of bone mineral content markers, decrease in the serum and urinary levels of bone resorption markers." | 3.80 | Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. ( Abbagoni, S; Banji, D; Banji, OJ; Chiluka, VL, 2014) |
| "For alendronate, the adjusted risk of major osteoporotic fractures was significantly reduced (OR 0." | 3.79 | Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. ( Abrahamsen, B; Hansen, C; Olsen, KR, 2013) |
| " The objective of this study was to investigate the association between AGS and persistence with alendronate treatment of primary osteoporosis in Sweden." | 3.78 | The association between automatic generic substitution and treatment persistence with oral bisphosphonates. ( Landfeldt, E; Ström, O, 2012) |
| "Before the drugs were started, patients later initiating alendronate or raloxifene had fewer strokes than the controls." | 3.77 | Stroke in relation to use of raloxifene and other drugs against osteoporosis. ( Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P, 2011) |
| "Bisphosphonates (BP), especially alendronate and risedronate, are the drugs most commonly used for osteoporosis treatment, being incorporated into the skeleton where they inhibit bone resorption and are thereafter slowly released during bone turnover." | 3.77 | Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. ( Guañabens, N; Martínez-Ferrer, A; Monegal, A; Olivares, V; Peris, P; Reyes, R; Torra, M, 2011) |
| "One of the patients was treated with alendronate therapy in concern of her risk factors for osteoporosis (her previous a hysterectomy with bilateral oophorectomy) with unsubstantiated evidence of her pretreatment, bone-mineral-density measurements (BMD), for a 10-year prior episode of left prodromal thigh pain and an insufficiency fracture at 8 days post experiencing the pain." | 3.77 | Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. ( Angthong, C; Angthong, W, 2011) |
| " Six-month-old Sprague-Dawley OVX rats (n=60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis." | 3.76 | Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. ( Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S, 2010) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1-hydroxyethylidenebis(phosphonic acid) (risedronic acid, 2), an osteoporosis drug that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, preventing protein prenylation." | 3.76 | Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. ( Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 3.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "A 77-year-old man, treated with risedronic acid to prevent corticosteroid-induced osteoporosis, was admitted to hospital with acute abdominal pain." | 3.74 | [Severe oesophagus injury as a complication during treatment with risedronic acid]. ( Bijlsma, A; Blokzijl, H; Vecht, J, 2008) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| "Patients were eligible for inclusion if they had osteoporosis or osteopenia and demonstrated a decline in BMD during the preceding year while taking stable doses of alendronate or risedronate, plus supplemental calcium and vitamin D." | 3.74 | Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. ( Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S, 2008) |
| "Treatment with alendronate was associated with significantly greater improvements in lumbar spine BMD within one year in breast cancer survivors when compared with treatment with cyclic etidronate or calcium and vitamin D." | 3.73 | Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? ( Adachi, JD; Boulos, P; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Kouroukis, T; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2005) |
| "Investigators identified a continuously benefit-eligible cohort of women from a large, geographically diverse, national managed care plan who were newly diagnosed and treated for osteoporosis with alendronate, risedronate, or raloxifene." | 3.73 | Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. ( Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA, 2006) |
| " Etidronate and alendronate are most cost effective in women with borderline osteoporosis (t scores of -1." | 3.72 | A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. ( Buckley, LM; Hillner, BE, 2003) |
| "Three simple, accurate and sensitive spectrophotometric methods are developed for the determination of some new drugs for the treatment of osteoporosis: risedronate sodium (I), alendronate sodium (II) and etidronate disodium (III)." | 3.72 | Spectrophotometric determination of some drugs for osteoporosis. ( Taha, EA; Youssef, NF, 2003) |
| "We performed an observational study of 1588 patients (163 men, 1425 women), 50 years of age and older, who were prescribed cyclic etidronate or alendronate for treatment of osteoporosis or osteopenia and had at least 2 years of followup registered in the Canadian Database for Osteoporosis and Osteopenia Patients (CANDOO)." | 3.72 | Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices? ( Adachi, JD; Brown, JP; Davison, KS; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2004) |
| "To compare the bone-mass effects of intermittent cyclic etidronate administration in patients of various rheumatic disease patients with corticosteroid-induced osteoporosis." | 3.71 | [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis]. ( Koshiba, M; Kumagai, S; Maekawa, S; Morinobu, A; Morinobu, S; Nakamura, T; Sugimoto, T; Yamauchi, M, 2002) |
| "We identified patients aged > or = 20 years who received prescriptions for > or = 2 g of prednisone (or equivalent) during any 12-month period between January 1, 1998, and December 31, 1999, and who initiated use of osteoporosis-specific drugs (alendronate sodium, etidronate disodium, and calcitonin) during that period." | 3.71 | Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. ( Chidambaran, P; Ettinger, B; Pressman, A, 2001) |
| "Clodronate, etidronate and pamidronate are bisphosphonates introduced in the treatment of hypercalcaemia and osteoporosis." | 3.70 | Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. ( Kalliovalkama, J; Kankaanranta, H; Lähteenmäki, T; Pörsti, I; Salenius, JP; Sisto, T; Wu, X; Ylitalo, P; Ylitalo, R, 1998) |
| "In an open prospective study, we evaluated differences between patients with (wRVF group) and without recurrence of vertebral fracture (woRVF group) during cyclical etidronate therapy for osteoporosis." | 3.70 | Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation. ( Alexandre, C; Barou, O; Lafage-Proust, MH; Thomas, T; Vico, L, 1999) |
| "Appropriate osteoporosis treatment was defined as alendronate, etidronate, calcitonin, or hormone replacement therapy (HRT) for women with any bone mineral density (BMD) t score < -2." | 3.70 | Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. ( Helfgott, SM; Levin, E; Solomon, DH, 2000) |
| "Inhibition of skeletal mineralisation is a well-recognized complication of disodium etidronate therapy that was identified in the earliest studies of its use in osteoporosis and Paget's disease." | 3.70 | Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. ( MacGowan, JR; Morris, VH; Pringle, J; Stamp, TC, 2000) |
| "Our clinical practice has been to offer treatment with cyclical disodium etidronate and high dose calcium supplements (1500-1600 mg/day) to all female patients with osteoporosis who are unable or unwilling to take hormone replacement therapy (HRT), and male osteoporotics." | 3.69 | Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. ( Belchetz, PE; Oldroyd, B; Orme, SM; Simpson, M; Smith, MA; Stewart, SP; Westmacott, CF, 1994) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| "to investigate the effects of oral intermittent cyclical etidronate therapy on bone mineral density (BMD) in men with idiopathic vertebral osteoporosis." | 3.69 | Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. ( Anderson, FH; Bishop, JC; Francis, RM; Rawlings, DJ, 1997) |
| " A group of 7977 cyclical etidronate takers and 2 age-, gender-, and practice-matched control groups (1 with osteoporosis and 1 without) were analyzed." | 3.69 | Upper gastrointestinal adverse events and cyclical etidronate. ( Abenhaim, L; Cooper, C; van Staa, T, 1997) |
| "The efficacy of the biphosphonate etidronate has recently been demonstrated versus the vertebral fracture rate in fractured involuted osteoporosis in the literature." | 3.68 | [Bone histomorphometric study in involuted fractured osteoporosis treated with 1-ethane-1-hydroxybiphosphonate (etidronate) during one year]. ( Alexandre, C; Chappard, D; Pallot-Prades, B; Prallet, B; Riffat, G; Tavan, P, 1991) |
| " Attempts to prevent disuse osteoporosis with both mechanical and biochemical means, including exercise, skeletal compression, increased hydrostatic pressure to the lower body, supplemental calcium and/or phosphorus, calcitonin, or etidronate were not successful." | 3.67 | Skeletal calcium homeostasis and countermeasures to prevent disuse osteoporosis. ( McDonald, J; Schneider, VS, 1984) |
| " Two groups of patients with either low (osteoporosis), (n = 15) or high (Paget's disease, n = 6) bone turnover were studied before and after sodium fluoride (NaF) and diphosphonate (EHDP) treatment, respectively." | 3.65 | Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease. ( Dambacher, MA; Guncaga, J; Haas, HG; Lauffenburger, T; Lentner, C; Olah, AJ, 1977) |
| "Osteoporosis is the most prevalent metabolic bone disorder worldwide." | 2.82 | Comparing the Efficacies of Bisphosphonates' Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. ( Almohaileb, FI; Rasheed, Z, 2022) |
| " Bone mineral density (BMD), biochemical markers of bone metabolism, fractures, and adverse events (AEs) were evaluated." | 2.79 | Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. ( Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H, 2014) |
| " A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively)." | 2.78 | The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. ( Itoh, S; Sekino, Y; Shinomiya, K; Takeda, S, 2013) |
| "Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis." | 2.77 | Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. ( Fedorak, RN; McQueen, B; Siffledeen, J; Siminoski, K; Soo, I, 2012) |
| " The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results." | 2.77 | Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. ( Boonen, S; Eusebio, R; Lorenc, RS; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2012) |
| "Treatment with etidronate suppressed this increase." | 2.76 | Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy. ( Furukawa, F; Hata, M; Hattori, M; Ikeda, T; Kaminaka, C; Kanazawa, N; Nishide, T; Ohta, C; Tsujioka, K; Uede, K; Yamamoto, Y, 2011) |
| "Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss." | 2.76 | Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. ( Izumi, K; Kitagawa, Y; Koh, E; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K, 2011) |
| "Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis." | 2.76 | Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. ( Fujii, Y; Fujita, T; Miyauchi, A; Nakajima, M; Ohue, M; Takagi, Y, 2011) |
| "Secondary outcomes included changes in bone resorption (betaCTX) and 12-month changes in BMD." | 2.75 | Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. ( Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B, 2010) |
| "Steroid-induced osteoporosis is a serious adverse effect of this drug." | 2.75 | Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. ( Amemiya, N; Itabashi, M; Karasawa, K; Kawanishi, K; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Shimizu, A; Shiohira, S; Sugiura, H; Takei, T; Tsuchiya, K; Tsukada, M; Uchida, K, 2010) |
| "Osteoporosis is a common condition in men that can have serious clinical consequences." | 2.74 | Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2009) |
| "Male osteoporosis is increasingly recognized as a major public health issue." | 2.74 | Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. ( Boonen, S; Delmas, PD; Eusebio, R; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2009) |
| " Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose." | 2.74 | Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. ( Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009) |
| "Urinary deoxypyridinoline, a bone resorption marker, decreased by 46." | 2.73 | Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007) |
| "Proximal bone resorption around the femoral stem often has been observed after total hip arthroplasty (THA), could lead to late stem loosening." | 2.73 | Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. ( Fuji, T; Masuhara, K; Nakai, T; Seino, Y; Yamaguchi, K; Yamasaki, S, 2007) |
| "Osteoporosis is a common adverse reaction induced by glucocorticoid treatment." | 2.73 | Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. ( Ichimura, A; Iwata, H; Nakajima, T; Ochiai, H; Takagi, H; Toriyama, T; Tsuchiya, H; Yamada, S, 2007) |
| "Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture." | 2.73 | Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. ( Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K, 2007) |
| "Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after fracture among men compared with women." | 2.72 | Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2006) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients." | 2.72 | Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. ( Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H, 2006) |
| "In this multicenter, randomized, double-blind controlled trial, the efficacy and safety of once-weekly dosing with 17." | 2.72 | Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. ( Fukunaga, M; Itabashi, A; Kishimoto, H; Kushida, K; Nakamura, T; Nawata, H; Ohashi, Y; Ohta, H; Shiraki, M; Takaoka, K, 2006) |
| "To determine the clinical recommended dosage regimen of risedronate for the treatment of involutional osteoporosis in Japanese patients, dose-response relationships for the efficacy and safety of this drug were investigated using a multi-center, randomized, double-blind, parallel group comparative design with four dose levels of risedronate (placebo, 1 mg, 2." | 2.71 | A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2003) |
| " Therefore, the pharmacokinetic profile of risedronate was considered to show linearity in a dosage range of up to 20 mg." | 2.71 | Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. ( Cyong, JC; Gonsho, A; Ogura, Y; Orimo, H, 2004) |
| "One hundred fifty-four patients with Crohn's disease with decreased bone mineral density, determined by using dual-energy x-ray absorptiometry, were randomly assigned to receive etidronate (400 mg orally) or not for 14 days; both groups were then given daily calcium (500 mg) and vitamin D (400 IU) supplementation for 76 days." | 2.71 | Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. ( Abraham, N; Fedorak, RN; Greenberg, G; Jen, H; Siffledeen, JS; Siminoski, K; Steinhart, H; Vaudan, E, 2005) |
| "Osteoporosis is a well-recognized adverse effect of corticosteroid therapy." | 2.69 | Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. ( Cortet, B; Di Munno, O; Goemaere, S; Horlait, S; Hughes, RA; Ittner, J; Laan, R; Oriente, P; Pouillès, JM; Roux, C, 1998) |
| " Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events." | 2.69 | Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. ( Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH, 2000) |
| "Osteopenia is a major complication of orthotopic liver transplantation (OLT)." | 2.68 | Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. ( Hawkins, F; Larrodera, L; Leon, M; Loinaz, C; Moreno, E; Valero, MA, 1995) |
| "Osteoporosis is a recognized complication of corticosteroid therapy." | 2.68 | Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. ( Adachi, JD; Bensen, WG; Brown, J; Chines, AA; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; Ste-Marie, LG; Tenenhouse, A, 1997) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "After patients with osteoporosis are identified, the challenge is to treat them appropriately." | 2.47 | Treatments for osteoporosis in people with a disability. ( Smith, EM, 2011) |
| "Patients with primary biliary cirrhosis often have osteoporosis - either postmenopausal or secondary to the liver disease." | 2.47 | Bisphosphonates for osteoporosis in primary biliary cirrhosis. ( Bjelakovic, G; Giljaca, V; Gluud, C; Krstic, MN; Rudic, JS, 2011) |
| "The use of endocrine therapy in breast cancer represents one of the earliest molecular targeting strategies used in cancer treatment." | 2.46 | Challenges in clinical patient management. ( Aapro, MS, 2010) |
| "Treatment with menatetrenone, risedronate or regular sunlight exposure are safe and effective in increasing bone mass and reducing the risk of hip fracture in patients with AD." | 2.46 | [Dementia and fracture]. ( Sato, Y, 2010) |
| "Male osteoporosis is an important public health issue and remains undertreated." | 2.45 | Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. ( Chen, JT; Zhong, ZM, 2009) |
| "Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts." | 2.45 | [Risedronate for treatment of osteoporosis]. ( Hagino, H, 2009) |
| " Fracture trials were initially performed with daily formulations, then bridging trials, in which the efficacy of intermittent dosing was assessed versus daily using validated surrogate endpoints for fracture." | 2.45 | Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. ( Epstein, S; Jeglitsch, M; McCloskey, E, 2009) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | 2.44 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008) |
| "5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen." | 2.44 | [Efficacy and tolerability of risedronate for the treatment of osteoporosis]. ( Kishimoto, H, 2008) |
| "They are indicated for the treatment of osteoporosis." | 2.44 | Osteochemonecrosis of jaws and bisphosphonates. ( Beirne, JC; Khosa, AD; Nayyar, MS, 2007) |
| " In placebo controlled trials it has been shown to be safe and effective in preventing fractures." | 2.44 | Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. ( Adachi, JD; Bobba, R, 2007) |
| "Osteoporosis is a serious public health issue." | 2.44 | Osteoporosis--from hormonal replacement therapy to bisphosphonates and beyond: a review. ( Kariuki, JG; Oyoo, GO, 2007) |
| "Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures." | 2.44 | Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. ( Iwamoto, J; Matsumoto, H; Takeda, T, 2008) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.43 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005) |
| "Clinically, osteoporosis is diagnosed using dual energy x-ray absorptiometry." | 2.43 | Microcracks in cortical bone: how do they affect bone biology? ( Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ, 2005) |
| " The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used." | 2.43 | Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006) |
| "In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate." | 2.43 | [Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005) |
| "RSD is available for the treatment of osteoporosis." | 2.42 | [Risedronate]. ( Fukunaga, M, 2003) |
| "Osteoporosis is associated with increased risk of fractures at most skeletal sites." | 2.42 | [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint]. ( Sohen, S, 2003) |
| " The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate." | 2.42 | Bisphosphonates: new indications and methods of administration. ( Reid, IR, 2003) |
| "In recent years, treatments for osteoporosis have been developing rapidly, and many of these research results have been reported." | 2.42 | [Bone quality in treatment with raroxifene ]. ( Nakamura, T, 2004) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "Etidronate disodium is an oral bisphosphonate compound known to reduce bone resorption through the inhibition of osteoclastic activity." | 2.41 | Etridronate therapy in the treatment and prevention of osteoporosis. ( Adachi, JD; Hanley, DA; Ioannidis, G, 2000) |
| "The diagnosis and treatment of osteoporosis is an important aspect of gynecologic training and practice." | 2.41 | Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature. ( Jennings, JC; Kauffman, RP; Overton, TH; Shiflett, M, 2001) |
| " Some bisphosphonates have been associated with upper gastrointestinal (GI) tract adverse effects." | 2.41 | Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. ( Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H, 2002) |
| "Many of the bisphosphonates inhibit bone resorption, the newest compounds being 10,000 times more active than etidronate, the first bisphosphonate described." | 2.40 | Bisphosphonates: preclinical aspects and use in osteoporosis. ( Fleisch, HA, 1997) |
| "Although osteoporosis is generally regarded as a disease of women, up to 30% of hip fractures and 20% of vertebral fractures occur in men." | 2.40 | Management of male osteoporosis: report of the UK Consensus Group. ( Boyle, IT; Compston, J; Cooper, C; Eastell, R; Fogelman, I; Francis, RM; Hosking, DJ; Purdie, DW; Ralston, S; Reeve, J; Reid, DM; Russell, RG; Stevenson, JC, 1998) |
| "The amount of bone loss in algodystrophy in a few weeks or months is what might be expected over 10 years during the natural history of uncomplicated osteoporosis." | 2.40 | Further vascular, bone and autonomic investigations in algodystrophy. ( Audran, M; Baslé, MF; Bregeon, C; Legrand, E; Masson, C; Namour, A; Pascaretti, C; Renier, JC; Saumet, JL, 1998) |
| "New approaches to treatment of osteoporosis will emerge as our understanding of the pathogenesis increases." | 2.39 | Treatment of osteoporosis. ( Pilbeam, CC; Prestwood, KM; Raisz, LG, 1995) |
| "Osteoporosis is greatly increasing in prevalence as the population ages." | 2.39 | Office management of osteoporosis: a guide for the primary care provider. ( Daly, PA, 1995) |
| "The source of most hip fractures is the community." | 2.39 | Present and future of osteoporosis therapy. ( Bass, S; Pearce, G; Seeman, E; Tsalamandris, C, 1995) |
| " Oestrogens are still the mainstay of drug treatment, but the risks of breast cancer versus the cardiovascular and skeletal benefits with long term use have to be assessed in the individual." | 2.39 | Current and potential future drug treatments for osteoporosis. ( Patel, S, 1996) |
| "Type I osteoporosis affects women 10-15 years after menopause and involves primarily trabecular bone while Type II, senile osteoporosis, results in hip fractures in both sexes." | 2.38 | Osteoporosis. ( Ullrich, I, 1991) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| "Etidronate is a non-nitrogen-containing bisphosphonate." | 1.56 | History of etidronate. ( Chesnut, CH; Genant, HK; Harris, ST; Jackson, RD; Licata, AA; Miller, PD; Mysiw, WJ; Richmond, B; Valent, D; Watts, NB, 2020) |
| "Despite the lack of consensus on the treatment of osteoporosis in NF1, risedronate may hold a promise as a potential therapy for osteoporosis complicating NF1." | 1.42 | Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. ( Benlidayi, IC; Kozanoglu, E; Ortac, EA, 2015) |
| "Multiple therapies are approved for the treatment of osteoporosis (OP), but many patients with osteoporosis may not initiate treatment upon osteoporosis diagnosis." | 1.40 | Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. ( Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J, 2014) |
| " Determinants associated with higher risk to non-persistence within the first year were daily dosing regimen [HR, 1." | 1.39 | Persistence with osteoporosis medication among newly-treated osteoporotic patients. ( de Boer, PT; Postma, MJ; van Boven, JF; Vegter, S, 2013) |
| "This study examined Barrett's esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates." | 1.39 | Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. ( Alsarraj, A; El-Serag, HB; Graham, DY; Kramer, JR; Lin, D; Parente, P; Ramsey, D; Rugge, M; Verstovsek, G, 2013) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Both RAL and RIS could treat osteoporosis in ORX rats; they reduced bone turnover markers and maintained BMD." | 1.39 | Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. ( El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF, 2013) |
| " However, an inverse dose-response relationship was seen, with an increased risk in those with low adherence (≤0." | 1.38 | Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? ( Vestergaard, P, 2012) |
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment." | 1.38 | The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012) |
| "Osteoporotic fractures are associated with premature mortality." | 1.37 | Osteoporosis medication and reduced mortality risk in elderly women and men. ( Bliuc, D; Center, JR; Eisman, JA; Nguyen, ND; Nguyen, TV, 2011) |
| " Although existing evidence supports a good safety profile, there is concern that chronic administration of these agents could result in severe suppression of bone turnover with increased risk of nonvertebral fractures." | 1.36 | Unusual mid-shaft fractures during long-term bisphosphonate therapy. ( Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE, 2010) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | 1.36 | Intravenous zoledronic acid: what are the indications for male osteoporosis? ( Maricic, M, 2010) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| " Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders." | 1.35 | Maximizing effectiveness of bisphosphonate therapy for osteoporosis. ( Martens, MG; Shaw, H, 2008) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| " Patients remarkably preferred therapy with a proven antifracture efficacy over a dosage frequency." | 1.35 | [Differences among bisfosfonates--specificity of risedronate (Actonel)]. ( Giljević, Z, 2008) |
| " Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise." | 1.35 | Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009) |
| "A total of 196 consecutive patients treated for distal radius fractures were included in this study." | 1.35 | Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009) |
| " Interpretations from this study are limited by assumptions of persistence based on initial drug dosing and selected refill gap length measured." | 1.35 | Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. ( Gold, DT; Safi, W; Trinh, H, 2009) |
| "A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone naïve)." | 1.35 | [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. ( Bab, S; Hayakawa, K; Hyodo, T; Iwamura, M; Kimura, M; Matsumoto, K; Okazaki, M; Satoh, T; Soh, S; Tabata, K; Tsuboi, T; Yokoyama, E, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| "Subjects were 17 postmenopausal breast cancer patients (mean age, 63." | 1.34 | Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. ( Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y, 2007) |
| "Osteoporosis is a severe complication of glucocorticoid treatment." | 1.34 | Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007) |
| "A history of fracture and a low bone mineral density (BMD) are the strongest predictors of future osteoporotic fracture." | 1.33 | Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. ( Adachi, JD; Goldsmith, CH; Hamel, ME; Papadimitropoulos, E; Petrie, A; Sebaldt, RJ; Siminoski, K, 2005) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy." | 1.33 | Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol. ( Ando, K; Higashi, M; Ichinose, H; Kanaji, A; Nakagawa, M; Namisato, M; Sakamaki, T; Yamada, H; Yato, Y, 2005) |
| "If patients with osteoporosis are being diagnosed and effective treatments used with increasing frequency in the population, rates of hip and wrist fractures will remain stable or possibly decrease." | 1.33 | Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? ( Adachi, JD; Hawker, G; Jaakkimainen, L; Jaglal, SB; Kreder, H; Mamdani, M; Weller, I, 2005) |
| "Osteoporosis is a serious and common condition with very high associated healthcare costs." | 1.33 | A bright future for osteoporosis treatment. ( Jack, D, 2005) |
| "The bisphosphonates, widely used in the treatment of osteoporosis, act by inhibiting bone resorption." | 1.33 | High-throughput in vivo screening for bone anabolic compounds with zebrafish. ( Fleming, A; Goldsmith, P; Sato, M, 2005) |
| " Although bisphosphonates are effective in treatment of osteoporosis, a strict instruction to patients on the dosage often results in their inadequate compliance with the therapy." | 1.33 | [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine]. ( Ijiri, S, 2005) |
| " The dosage regimen could be simplified by providing the two compounds in an integrated pack." | 1.33 | Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. ( Möller, G; Ringe, JD; van der Geest, SA, 2006) |
| "In the rats with adjuvant arthritis, BMD of either end of the tibia was lower than in normal rats." | 1.33 | Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts. ( Nagashima, M; Shu, G; Yamamoto, K, 2006) |
| " The most frequently reported adverse events are gastrointestinal complaints and oesophageal ulcers." | 1.32 | [Psychiatric side effects associated with diphosphonate treatment]. ( van der Klauw, MM; Wolffenbuttel, BH, 2003) |
| "The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice." | 1.32 | Tolerability and compliance with risedronate in clinical practice. ( Hamilton, B; McCoy, K; Taggart, H, 2003) |
| "Kynurenine analysis was performed by HPLC." | 1.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| "Most CR investigated and treated osteoporosis themselves, 13% referred to other specialists for investigation, and 22% referred for treatment." | 1.31 | A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. ( Adachi, JD; Bellamy, N; Campbell, J; Flynn, J; Pope, JE; Soucy, E; Sutton, E, 2000) |
| " The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat." | 1.31 | Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000) |
| " The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described." | 1.31 | Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. ( Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000) |
| "Osteoporosis is a well-documented complication of organ transplantation." | 1.31 | Treatment of established bone loss after renal transplantation with etidronate. ( Adachi, JD; Arlen, DJ; Ioannidis, G; Lambert, K, 2001) |
| "Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks." | 1.31 | Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. ( Ichimura, S; Iwamoto, J; Katsumata, T; Takeda, T; Tanaka, T; Toyama, Y, 2002) |
| "Issues relating to the treatment of the osteoporosis as well as the lymphoma arise in patients that present in this way." | 1.31 | Lymphoplasmacytoid lymphoma presenting as severe osteoporosis. ( Atoyebi, W; Brown, M; Hatton, C; Littlewood, TJ; Wass, J, 2002) |
| "With respect to markers of bone resorption, urinary deoxypyridinoline fell by 51% +/- 9% in group A patients and increased by 65% +/- 22% in group B patients by 3 months after transplantation (P < ." | 1.30 | Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. ( Addesso, V; Lo, SH; Mancini, D; McMahon, DJ; Michler, RE; Rodino, MA; Seibel, MJ; Shane, E; Staron, RB, 1998) |
| "Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures." | 1.29 | Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. ( Kochman, ML; Melton, ME, 1994) |
| "When osteoporosis is diagnosed in men or premenopausal women, underlying pathology could be considered." | 1.29 | [Systemic mastocytosis as a cause of osteoporosis]. ( Kemink, SA; Kloppenborg, PW; Smals, AG, 1996) |
| " Direct analyses of dog bones either 90 days after a single dose or 365 days after cessation of chronic dosing indicate a more rapid bone clearance of EHDP than predicted by the initial power law." | 1.28 | Retention of etidronate in human, dog, and rat. ( Francis, MD; Kasting, GB, 1992) |
| "The present study was undertaken to test whether long term administration of HEBP could prevent the progress of bone loss induced by ovariectomy in rats." | 1.28 | Effect of HEBP (1-hydroxyethylidene-1,1-bisphosphonate) on experimental osteoporosis induced by ovariectomy in rats. ( Arai, M; Hironaka, M; Matsumoto, S; Shinoda, H; Togari, A, 1991) |
| "Osteoclastic bone resorption is activated by 7 days of oral neutral phosphate and inhibited with a brief pulse (5 days) of etidronate disodium at a high dose (20 mg/kg body weight)." | 1.28 | Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. ( LeBlanc, AD; Mallette, LE; Mechanick, JI; Pool, JL, 1989) |
| "Acute osteoporosis is known to occur after immobilization in spinal cord injured patients and is related to an early increase in osteoclastic bone resorption." | 1.28 | Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. ( Alexandre, C; Chappard, D; Minaire, P; Morukov, BV; Palle, S; Riffat, G; Rodionova, SS; Vico, L, 1989) |
| "Osteomalacia is caused by inadequate or delayed mineralization of bone and is treated by correcting the abnormal intake, loss, or metabolism of vitamin D, phosphate, and calcium." | 1.27 | Osteoporosis, osteomalacia, rickets, and Paget's disease. ( Gall, EP; Nugent, CA; Pitt, MJ, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (4.52) | 18.7374 |
| 1990's | 95 (18.66) | 18.2507 |
| 2000's | 277 (54.42) | 29.6817 |
| 2010's | 104 (20.43) | 24.3611 |
| 2020's | 10 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Thomasius, F | 4 |
| Palacios, S | 2 |
| Alam, A | 1 |
| Boolell, M | 2 |
| Vekeman, F | 2 |
| Gauthier, G | 1 |
| Waltman, N | 1 |
| Kupzyk, KA | 1 |
| Flores, LE | 1 |
| Mack, LR | 1 |
| Lappe, JM | 1 |
| Bilek, LD | 1 |
| Migliorini, F | 1 |
| Colarossi, G | 1 |
| Eschweiler, J | 1 |
| Oliva, F | 1 |
| Driessen, A | 1 |
| Maffulli, N | 1 |
| Eisman, JA | 4 |
| Cortet, B | 4 |
| Ionescu-Ittu, R | 1 |
| Heroux, J | 1 |
| Pham, CV | 1 |
| Pham, TT | 1 |
| Lai, TT | 1 |
| Trinh, DC | 1 |
| Nguyen, HVM | 1 |
| Ha, TTM | 1 |
| Phuong, TT | 1 |
| Tran, LD | 1 |
| Winkler, C | 1 |
| To, TT | 1 |
| Watts, NB | 3 |
| Chesnut, CH | 1 |
| Genant, HK | 2 |
| Harris, ST | 2 |
| Jackson, RD | 1 |
| Licata, AA | 5 |
| Miller, PD | 2 |
| Mysiw, WJ | 1 |
| Richmond, B | 1 |
| Valent, D | 1 |
| Avenell, A | 1 |
| Grey, A | 1 |
| Gamble, GD | 2 |
| Bolland, MJ | 2 |
| Alpert, JS | 1 |
| Stumpf, MJ | 1 |
| Schaefer, CA | 1 |
| Schahab, N | 1 |
| Almohaileb, FI | 1 |
| Rasheed, Z | 1 |
| Nikfar, Z | 1 |
| Shariatinia, Z | 1 |
| Liel, Y | 1 |
| Kendler, DL | 3 |
| Geusens, P | 7 |
| Zerbini, CAF | 1 |
| Minisola, S | 5 |
| Marin, F | 4 |
| Bliuc, D | 2 |
| Tran, T | 1 |
| van Geel, T | 1 |
| Adachi, JD | 20 |
| Berger, C | 1 |
| van den Bergh, J | 1 |
| Goltzman, D | 1 |
| Hanley, DA | 9 |
| Josse, RG | 5 |
| Kaiser, S | 1 |
| Kovacs, CS | 1 |
| Langsetmo, L | 1 |
| Prior, JC | 1 |
| Nguyen, TV | 2 |
| Center, JR | 2 |
| Hayes, KN | 1 |
| Ban, JK | 1 |
| Athanasiadis, G | 1 |
| Burden, AM | 1 |
| Cadarette, SM | 4 |
| van Boven, JF | 1 |
| de Boer, PT | 1 |
| Postma, MJ | 1 |
| Vegter, S | 1 |
| Olsen, KR | 1 |
| Hansen, C | 1 |
| Abrahamsen, B | 2 |
| Cosman, F | 1 |
| Sahana, H | 1 |
| Khajuria, DK | 1 |
| Razdan, R | 1 |
| Mahapatra, DR | 1 |
| Bhat, MR | 1 |
| Suresh, S | 1 |
| Rao, RR | 1 |
| Mariappan, L | 1 |
| Nakamura, T | 8 |
| Nakano, T | 1 |
| Ito, M | 2 |
| Hagino, H | 4 |
| Hashimoto, J | 1 |
| Tobinai, M | 1 |
| Mizunuma, H | 1 |
| Farahmand, P | 4 |
| Hawkins, F | 3 |
| Möricke, R | 2 |
| Ringe, JD | 11 |
| Glüer, CC | 2 |
| Papaioannou, N | 1 |
| Martínez, G | 2 |
| Nolla, JM | 2 |
| Niedhart, C | 2 |
| Guañabens, N | 3 |
| Nuti, R | 4 |
| Martín-Mola, E | 2 |
| Peña, J | 2 |
| Graeff, C | 2 |
| Kapetanos, G | 2 |
| Petto, H | 3 |
| Gentzel, A | 1 |
| Reisinger, A | 2 |
| Zysset, PK | 2 |
| Tanaka, S | 1 |
| Miyazaki, T | 1 |
| Uemura, Y | 1 |
| Kuroda, T | 1 |
| Miyakawa, N | 1 |
| Fukunaga, M | 7 |
| Ohashi, Y | 4 |
| Ohta, H | 3 |
| Mori, S | 1 |
| Hosoi, T | 2 |
| Sugimoto, T | 2 |
| Itoi, E | 1 |
| Orimo, H | 6 |
| Shiraki, M | 11 |
| Lin, D | 1 |
| Kramer, JR | 1 |
| Ramsey, D | 1 |
| Alsarraj, A | 1 |
| Verstovsek, G | 1 |
| Rugge, M | 1 |
| Parente, P | 1 |
| Graham, DY | 1 |
| El-Serag, HB | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Damm, DD | 1 |
| Jones, DM | 1 |
| Sato, Y | 9 |
| Honda, Y | 4 |
| Iwamoto, J | 12 |
| Amano, N | 1 |
| Iolascon, G | 1 |
| Gimigliano, F | 1 |
| Orlando, V | 1 |
| Capaldo, A | 1 |
| Di Somma, C | 2 |
| Menditto, E | 1 |
| Siris, ES | 1 |
| Modi, A | 1 |
| Tang, J | 1 |
| Gandhi, S | 1 |
| Sen, S | 1 |
| Kikuta, J | 1 |
| Ishii, M | 3 |
| Kishimoto, H | 9 |
| Ohishi, H | 1 |
| Horii, S | 1 |
| Banji, D | 1 |
| Banji, OJ | 1 |
| Chiluka, VL | 1 |
| Abbagoni, S | 1 |
| Shimano, RC | 1 |
| Macedo, AP | 1 |
| Falcai, MJ | 1 |
| Ervolino, E | 1 |
| Shimano, AC | 1 |
| Issa, JP | 1 |
| Soen, S | 2 |
| Pepe, J | 1 |
| Isidori, AM | 1 |
| Falciano, M | 1 |
| Iaiani, G | 1 |
| Salotti, A | 1 |
| Diacinti, D | 1 |
| Del Fiacco, R | 1 |
| Sbardella, E | 1 |
| Cipriani, C | 1 |
| Piemonte, S | 1 |
| Raimo, O | 1 |
| Biondi, P | 1 |
| Biamonte, F | 1 |
| Lenzi, A | 1 |
| Ström, O | 3 |
| Landfeldt, E | 3 |
| Garellick, G | 1 |
| Benlidayi, IC | 1 |
| Ortac, EA | 1 |
| Kozanoglu, E | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Phillips, R | 1 |
| Sestak, I | 1 |
| Singh, S | 1 |
| Cuzick, J | 1 |
| Blake, GM | 3 |
| Patel, R | 1 |
| Gossiel, F | 1 |
| Coleman, R | 1 |
| Dowsett, M | 1 |
| Forbes, JF | 1 |
| Howell, A | 1 |
| Eastell, R | 4 |
| Reid, IR | 4 |
| Suva, LJ | 1 |
| Makhoul, I | 1 |
| Babinets', LS | 2 |
| Semenova, IV | 2 |
| Borovyk, IO | 2 |
| Shah, S | 1 |
| Jeremiah, C | 1 |
| Johnson, D | 1 |
| Baker, S | 1 |
| Luckish, A | 1 |
| Cernes, R | 1 |
| Boaz, M | 1 |
| Gavish, D | 1 |
| Matas, Z | 1 |
| Fux, A | 1 |
| Shargorodsky, M | 1 |
| Iwasaki, T | 2 |
| Takei, K | 1 |
| Nakamura, S | 1 |
| Hosoda, N | 1 |
| Yokota, Y | 1 |
| Matsumoto, H | 4 |
| Takeda, T | 6 |
| Liu, X | 1 |
| Yeh, JK | 2 |
| Martens, MG | 1 |
| Shaw, H | 1 |
| Ruffoni, D | 1 |
| Fratzl, P | 1 |
| Roschger, P | 1 |
| Phipps, R | 4 |
| Klaushofer, K | 1 |
| Weinkamer, R | 1 |
| Lems, WF | 2 |
| Geusens, PP | 1 |
| Hochberg, MC | 2 |
| Faber, H | 2 |
| Dorst, A | 2 |
| Takada, J | 3 |
| Iba, K | 2 |
| Yamashita, T | 2 |
| Yoshizaki, T | 1 |
| Lakhotia, SM | 1 |
| Tang, SY | 1 |
| Allen, MR | 2 |
| Burr, DB | 4 |
| Vashishth, D | 1 |
| Bijlsma, A | 1 |
| Blokzijl, H | 1 |
| Vecht, J | 1 |
| Lawson, MA | 1 |
| Coulton, L | 1 |
| Ebetino, FH | 2 |
| Vanderkerken, K | 1 |
| Croucher, PI | 1 |
| Seki, A | 1 |
| Yamada, H | 3 |
| Curtis, JR | 4 |
| Westfall, AO | 3 |
| Cheng, H | 1 |
| Saag, KG | 5 |
| Delzell, E | 1 |
| Yokote, Y | 1 |
| Kimura, E | 1 |
| Kimura, M | 2 |
| Kozono, Y | 1 |
| Verhaar, HJ | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Giljević, Z | 2 |
| Boonen, S | 5 |
| Orwoll, ES | 2 |
| Wenderoth, D | 3 |
| Stoner, KJ | 2 |
| Eusebio, R | 2 |
| Delmas, PD | 3 |
| Hines, SL | 1 |
| Mincey, BA | 1 |
| Sloan, JA | 1 |
| Thomas, SP | 1 |
| Chottiner, E | 1 |
| Loprinzi, CL | 2 |
| Carlson, MD | 1 |
| Atherton, PJ | 2 |
| Salim, M | 1 |
| Perez, EA | 1 |
| Blouin, J | 2 |
| Dragomir, A | 2 |
| Fredette, M | 1 |
| Ste-Marie, LG | 5 |
| Fernandes, JC | 2 |
| Perreault, S | 2 |
| Okazaki, R | 1 |
| Inderjeeth, CA | 1 |
| Foo, AC | 1 |
| Lai, MM | 1 |
| Glendenning, P | 1 |
| Kruk, M | 1 |
| Ralston, SH | 3 |
| Albagha, OM | 1 |
| Matsumoto, T | 2 |
| Ohbayashi, H | 1 |
| Majima, T | 3 |
| Shimatsu, A | 2 |
| Komatsu, Y | 3 |
| Satoh, N | 2 |
| Fukao, A | 3 |
| Ninomiya, K | 2 |
| Matsumura, T | 2 |
| Nakao, K | 3 |
| Katz, JN | 3 |
| Brookhart, MA | 3 |
| Stürmer, T | 2 |
| Stedman, MR | 2 |
| Levin, R | 1 |
| Solomon, DH | 3 |
| Matsumoto, Y | 1 |
| Mikuni-Takagaki, Y | 1 |
| Kozai, Y | 1 |
| Miyagawa, K | 1 |
| Naruse, K | 1 |
| Wakao, H | 1 |
| Kawamata, R | 1 |
| Kashima, I | 1 |
| Sakurai, T | 1 |
| Odvina, CV | 1 |
| Levy, S | 1 |
| Rao, S | 1 |
| Zerwekh, JE | 1 |
| Rao, DS | 1 |
| Blumentals, WA | 1 |
| Cole, RE | 1 |
| Huang, L | 1 |
| Silverman, SL | 1 |
| Rozental, TD | 1 |
| Vazquez, MA | 1 |
| Chacko, AT | 1 |
| Ayogu, N | 1 |
| Bouxsein, ML | 1 |
| Gennari, L | 1 |
| Bilezikian, JP | 3 |
| Reid, DM | 9 |
| Devogelaer, JP | 7 |
| Saag, K | 3 |
| Roux, C | 6 |
| Lau, CS | 3 |
| Reginster, JY | 6 |
| Papanastasiou, P | 3 |
| Ferreira, A | 1 |
| Hartl, F | 1 |
| Fashola, T | 1 |
| Mesenbrink, P | 1 |
| Sambrook, PN | 5 |
| Zhong, ZM | 1 |
| Chen, JT | 1 |
| Uyar, Y | 1 |
| Baytur, Y | 1 |
| Inceboz, U | 1 |
| Demir, BC | 1 |
| Gumuser, G | 1 |
| Ozbilgin, K | 1 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Ye, Y | 1 |
| Hu, SJ | 1 |
| Kearns, AE | 1 |
| Northfelt, DW | 1 |
| Dueck, AC | 1 |
| Dakhil, SR | 1 |
| Rowland, KM | 1 |
| Fuloria, J | 1 |
| Flynn, PJ | 1 |
| Dentchev, T | 1 |
| Kriel, MH | 1 |
| Tobias, JH | 1 |
| Creed, TJ | 1 |
| Lockett, M | 1 |
| Linehan, J | 1 |
| Bell, A | 1 |
| Przemioslo, R | 1 |
| Smithson, JE | 1 |
| Brooklyn, TN | 1 |
| Fraser, WD | 1 |
| Probert, CS | 1 |
| Gold, DT | 1 |
| Trinh, H | 1 |
| Safi, W | 1 |
| Kwak, HB | 1 |
| Kim, JY | 1 |
| Kim, KJ | 1 |
| Choi, MK | 1 |
| Kim, JJ | 1 |
| Kim, KM | 1 |
| Shin, YI | 1 |
| Lee, MS | 1 |
| Kim, HS | 1 |
| Kim, JW | 1 |
| Chun, CH | 1 |
| Cho, HJ | 1 |
| Hong, GY | 1 |
| Juhng, SK | 1 |
| Yoon, KH | 1 |
| Park, BH | 1 |
| Bae, JM | 1 |
| Han, JK | 1 |
| Oh, J | 1 |
| Keel, C | 1 |
| Kraenzlin, ME | 1 |
| Kraenzlin, CA | 1 |
| Müller, B | 1 |
| Meier, C | 1 |
| Asano, S | 1 |
| Suzuki, A | 1 |
| Itoh, M | 2 |
| Willey, JS | 1 |
| Livingston, EW | 1 |
| Robbins, ME | 1 |
| Bourland, JD | 1 |
| Tirado-Lee, L | 1 |
| Smith-Sielicki, H | 1 |
| Bateman, TA | 1 |
| Chevalier, Y | 1 |
| Quek, E | 1 |
| Borah, B | 1 |
| Gross, G | 1 |
| Stewart, J | 1 |
| Lang, T | 1 |
| Zysset, P | 1 |
| Epstein, S | 2 |
| Jeglitsch, M | 1 |
| McCloskey, E | 2 |
| Feher, A | 1 |
| Koivunemi, A | 1 |
| Koivunemi, M | 1 |
| Fuchs, RK | 1 |
| Phipps, RJ | 2 |
| Reinwald, S | 1 |
| Bahlous, A | 1 |
| Bouzid, K | 1 |
| Sahli, H | 1 |
| Sallami, S | 1 |
| Abdelmoula, J | 1 |
| Vestergaard, P | 4 |
| Schwartz, K | 3 |
| Pinholt, EM | 3 |
| Rejnmark, L | 3 |
| Mosekilde, L | 5 |
| Grey, AB | 1 |
| Gates, BJ | 1 |
| Sonnett, TE | 1 |
| Duvall, CA | 1 |
| Dobbins, EK | 1 |
| Berto, P | 1 |
| Maggi, S | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Yamazaki, Y | 1 |
| Shiraki, Y | 1 |
| Tsugawa, N | 1 |
| Okano, T | 1 |
| McKenna, CE | 1 |
| Kashemirov, BA | 1 |
| Błazewska, KM | 1 |
| Mallard-Favier, I | 1 |
| Stewart, CA | 1 |
| Rojas, J | 1 |
| Lundy, MW | 1 |
| Baron, RA | 1 |
| Dunford, JE | 1 |
| Kirsten, ML | 1 |
| Seabra, MC | 1 |
| Bala, JL | 1 |
| Marma, MS | 1 |
| Rogers, MJ | 1 |
| Coxon, FP | 1 |
| Maricic, M | 3 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Taxel, P | 1 |
| Dowsett, R | 1 |
| Richter, L | 1 |
| Fall, P | 1 |
| Klepinger, A | 1 |
| Albertsen, P | 1 |
| Girgis, CM | 1 |
| Sher, D | 1 |
| Seibel, MJ | 3 |
| Furukawa, F | 1 |
| Kaminaka, C | 1 |
| Ikeda, T | 1 |
| Kanazawa, N | 1 |
| Yamamoto, Y | 1 |
| Ohta, C | 1 |
| Nishide, T | 1 |
| Tsujioka, K | 1 |
| Hattori, M | 1 |
| Uede, K | 1 |
| Hata, M | 1 |
| Takakuwa, M | 2 |
| Konishi, M | 1 |
| Zhou, Q | 1 |
| Itabashi, K | 2 |
| Leonida, A | 1 |
| Vescovi, P | 1 |
| Baldoni, M | 1 |
| Rossi, G | 1 |
| Lauritano, D | 1 |
| Aapro, MS | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Takei, T | 1 |
| Itabashi, M | 1 |
| Tsukada, M | 1 |
| Sugiura, H | 1 |
| Moriyama, T | 1 |
| Kojima, C | 1 |
| Shiohira, S | 1 |
| Shimizu, A | 1 |
| Karasawa, K | 1 |
| Amemiya, N | 1 |
| Kawanishi, K | 1 |
| Ogawa, T | 1 |
| Uchida, K | 1 |
| Tsuchiya, K | 1 |
| Nitta, K | 1 |
| Orita, S | 1 |
| Ohtori, S | 1 |
| Koshi, T | 1 |
| Yamashita, M | 1 |
| Yamauchi, K | 1 |
| Inoue, G | 1 |
| Suzuki, M | 1 |
| Eguchi, Y | 1 |
| Kamoda, H | 1 |
| Arai, G | 1 |
| Ishikawa, T | 1 |
| Miyagi, M | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Takaso, M | 1 |
| Aoki, Y | 1 |
| Toyone, T | 1 |
| Takahashi, K | 1 |
| Bachmeyer, C | 1 |
| Gauthier, M | 1 |
| Nguyen, ND | 1 |
| Vujasinovic-Stupar, N | 1 |
| Pejnovic, N | 1 |
| Markovic, L | 1 |
| Zlatanovic, M | 1 |
| Smith, EM | 1 |
| Fujita, Y | 1 |
| Watanabe, K | 1 |
| Uchikanbori, S | 1 |
| Maki, K | 1 |
| Izumi, K | 1 |
| Mizokami, A | 1 |
| Sugimoto, K | 1 |
| Narimoto, K | 1 |
| Kitagawa, Y | 1 |
| Koh, E | 1 |
| Namiki, M | 1 |
| Fujita, T | 2 |
| Ohue, M | 1 |
| Nakajima, M | 1 |
| Fujii, Y | 1 |
| Miyauchi, A | 1 |
| Takagi, Y | 1 |
| Geoffroy, V | 1 |
| Paschalis, EP | 1 |
| Libouban, H | 2 |
| Blouin, S | 1 |
| Ostertag, A | 1 |
| Chappard, D | 4 |
| Cros, M | 1 |
| de Vernejoul, MC | 1 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Chung, HY | 1 |
| Chin, SO | 1 |
| Kang, MI | 1 |
| Koh, JM | 1 |
| Moon, SH | 1 |
| Yoon, BK | 1 |
| Yoon, HK | 1 |
| Chung, YS | 1 |
| Park, HM | 1 |
| Lee, JH | 1 |
| Lee, SH | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Peris, P | 1 |
| Torra, M | 1 |
| Olivares, V | 1 |
| Reyes, R | 1 |
| Monegal, A | 1 |
| Martínez-Ferrer, A | 1 |
| Umeno, K | 1 |
| Hayashida, N | 1 |
| Hannon, RA | 1 |
| Rodriguez-Moreno, J | 1 |
| Sawicki, A | 1 |
| Ott, SM | 1 |
| Martin, KE | 1 |
| Yu, J | 1 |
| Campbell, HE | 1 |
| Abarca, J | 1 |
| White, TJ | 1 |
| Yurci, A | 1 |
| Kalkan, AO | 1 |
| Ozbakir, O | 1 |
| Karaman, A | 1 |
| Torun, E | 1 |
| Kula, M | 1 |
| Baskol, M | 1 |
| Gursoy, S | 1 |
| Yucesoy, M | 1 |
| Bayram, F | 1 |
| Bucci-Rechtweg, C | 3 |
| Su, G | 3 |
| Nam, SH | 1 |
| Jeong, JH | 1 |
| Che, X | 1 |
| Lim, KE | 1 |
| Nam, H | 1 |
| Park, JS | 1 |
| Choi, JY | 1 |
| Nonoda, Y | 1 |
| Rudic, JS | 1 |
| Giljaca, V | 1 |
| Krstic, MN | 1 |
| Bjelakovic, G | 1 |
| Gluud, C | 1 |
| Soo, I | 1 |
| Siffledeen, J | 1 |
| Siminoski, K | 4 |
| McQueen, B | 1 |
| Fedorak, RN | 2 |
| Pazianas, M | 1 |
| Wang, Y | 1 |
| Russell, RG | 4 |
| Markopoulos, C | 1 |
| Tzoracoleftherakis, E | 1 |
| Koukouras, D | 1 |
| Venizelos, B | 1 |
| Zobolas, V | 1 |
| Misitzis, J | 1 |
| Xepapadakis, G | 1 |
| Gogas, H | 1 |
| Davey, DA | 1 |
| Angthong, C | 1 |
| Angthong, W | 1 |
| Kim, TY | 1 |
| Ha, YC | 1 |
| Kang, BJ | 1 |
| Lee, YK | 1 |
| Koo, KH | 1 |
| Lorenc, RS | 1 |
| Khedr, NF | 1 |
| El-Ashmawy, NE | 1 |
| El-Bahrawy, HA | 1 |
| Haggag, AA | 1 |
| El-Abd, EE | 1 |
| Hemmati, I | 1 |
| Wade, J | 1 |
| Kelsall, J | 1 |
| Osawa, M | 1 |
| Yamaguchi, H | 1 |
| Iinuma, N | 1 |
| Hayakawa, Y | 1 |
| Suzuki, H | 1 |
| Kamisaki, T | 1 |
| Iwayama, S | 1 |
| Nishikawa, M | 1 |
| Walker, MD | 1 |
| Cusano, NE | 1 |
| Sliney, J | 1 |
| Romano, M | 1 |
| Zhang, C | 1 |
| McMahon, DJ | 2 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Itoh, S | 1 |
| Sekino, Y | 1 |
| Shinomiya, K | 1 |
| Takeda, S | 1 |
| Ferko, NC | 1 |
| Borisova, N | 1 |
| Airia, P | 1 |
| Grima, DT | 1 |
| Thompson, MF | 1 |
| Choo, R | 1 |
| Lukka, H | 1 |
| Cheung, P | 1 |
| Corbett, T | 1 |
| Briones-Urbina, R | 1 |
| Vieth, R | 1 |
| Ehrlich, L | 1 |
| Kiss, A | 1 |
| Danjoux, C | 1 |
| Papaioannu, N | 1 |
| Sanz, B | 1 |
| Sambrook, P | 3 |
| Goemaere, S | 2 |
| Ish-Shalom, S | 1 |
| Collette, J | 1 |
| Erben, RG | 1 |
| Thomsen, JS | 2 |
| Weber, K | 1 |
| Stahr, K | 1 |
| Leyshon, A | 1 |
| Smith, SY | 1 |
| Välimäki, MJ | 1 |
| Maekawa, S | 1 |
| Morinobu, S | 1 |
| Morinobu, A | 1 |
| Koshiba, M | 1 |
| Yamauchi, M | 1 |
| Kumagai, S | 1 |
| Collier, J | 1 |
| Srivastava, M | 1 |
| Deal, C | 1 |
| Kushida, K | 3 |
| Taketani, Y | 2 |
| Minaguchi, H | 2 |
| Inoue, T | 3 |
| Morita, R | 3 |
| Morii, H | 2 |
| Yamamoto, K | 4 |
| Baranauskaite, A | 2 |
| Savickiene, A | 1 |
| Minne, HW | 2 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Buckley, LM | 1 |
| Hillner, BE | 1 |
| Wolffenbuttel, BH | 1 |
| van der Klauw, MM | 1 |
| Bartl, R | 2 |
| Inui, K | 1 |
| Takaoka, K | 6 |
| Sohen, S | 1 |
| Hamilton, B | 1 |
| McCoy, K | 1 |
| Taggart, H | 2 |
| Prestwood, KM | 3 |
| Raisz, LG | 3 |
| Traut, V | 1 |
| Larocque, D | 1 |
| Yamaguchi, K | 2 |
| Masuhara, K | 2 |
| Yamasaki, S | 2 |
| Nakai, T | 2 |
| Fuji, T | 2 |
| Tauchmanovà, L | 1 |
| Selleri, C | 1 |
| Esposito, M | 1 |
| Orio, F | 1 |
| Bifulco, G | 1 |
| Palomba, S | 1 |
| Lombardi, G | 1 |
| Rotoli, B | 1 |
| Colao, A | 1 |
| Papaioannou, A | 5 |
| Ioannidis, G | 10 |
| Sebaldt, RJ | 9 |
| Ferko, N | 1 |
| Puglia, M | 1 |
| Brown, J | 4 |
| Tenenhouse, A | 6 |
| Olszynski, WP | 6 |
| Boulos, P | 2 |
| Josse, R | 4 |
| Murray, TM | 4 |
| Petrie, A | 7 |
| Goldsmith, CH | 8 |
| Ettinger, MP | 2 |
| Taha, EA | 1 |
| Youssef, NF | 1 |
| Miller, L | 1 |
| Grynpas, M | 1 |
| Li, J | 1 |
| Boyde, A | 1 |
| Mashiba, T | 2 |
| Hirano, T | 2 |
| Johnston, CC | 2 |
| Cohen, SB | 1 |
| Sawka, AM | 3 |
| Brown, JP | 6 |
| Murray, T | 1 |
| Sato, S | 3 |
| Ohosone, Y | 1 |
| Suwa, A | 2 |
| Yasuoka, H | 1 |
| Nojima, T | 1 |
| Fujii, T | 1 |
| Kuwana, M | 2 |
| Nakamura, K | 1 |
| Mimori, T | 1 |
| Hirakata, M | 2 |
| Naganathan, V | 1 |
| Barton, I | 4 |
| Grauer, A | 1 |
| Ogura, Y | 2 |
| Gonsho, A | 2 |
| Cyong, JC | 2 |
| Nakatsuka, K | 1 |
| Miki, T | 1 |
| Naka, H | 2 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Ishii, S | 1 |
| Kobayashi, S | 4 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Forrest, CM | 1 |
| Kennedy, A | 1 |
| Stone, TW | 1 |
| Stoy, N | 1 |
| Darlington, LG | 1 |
| Jiang, G | 1 |
| Yamane, J | 1 |
| Kuboyama, N | 1 |
| Akimoto, Y | 1 |
| Fujii, A | 1 |
| Campbell, IA | 1 |
| Douglas, JG | 1 |
| Francis, RM | 3 |
| Prescott, RJ | 1 |
| Ott, S | 1 |
| Marx, J | 1 |
| Vanderschueren, D | 1 |
| Thabane, L | 2 |
| Davison, KS | 2 |
| Henderson, MJ | 1 |
| Hamel, ME | 1 |
| Papadimitropoulos, E | 1 |
| Kanaji, A | 2 |
| Higashi, M | 2 |
| Namisato, M | 2 |
| Ando, K | 2 |
| Nakagawa, M | 1 |
| Yato, Y | 1 |
| Ichinose, H | 1 |
| Sakamaki, T | 1 |
| Li, CY | 1 |
| Price, C | 1 |
| Delisser, K | 1 |
| Nasser, P | 1 |
| Laudier, D | 1 |
| Clement, M | 1 |
| Jepsen, KJ | 1 |
| Schaffler, MB | 1 |
| Ortego-Centeno, N | 1 |
| Muñoz-Torres, M | 1 |
| Callejas-Rubio, JL | 1 |
| Riera-Montes, M | 1 |
| Lange, U | 1 |
| Illgner, U | 1 |
| Teichmann, J | 1 |
| Schleenbecker, H | 1 |
| Siffledeen, JS | 1 |
| Jen, H | 1 |
| Vaudan, E | 1 |
| Abraham, N | 1 |
| Steinhart, H | 1 |
| Greenberg, G | 1 |
| Sebba, AI | 1 |
| Bonnick, SL | 1 |
| Kagan, R | 1 |
| Thompson, DE | 1 |
| Skalky, CS | 1 |
| Chen, E | 1 |
| de Papp, AE | 1 |
| Allali, F | 1 |
| Guedirra, N | 1 |
| Hajjaj-Hassouni, N | 1 |
| Jaglal, SB | 2 |
| Hawker, GA | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Pande, I | 2 |
| Hosking, DJ | 4 |
| Weller, I | 1 |
| Mamdani, M | 1 |
| Hawker, G | 1 |
| Kreder, H | 1 |
| Jaakkimainen, L | 1 |
| Melton, LJ | 1 |
| Kanis, JA | 3 |
| Johnell, O | 1 |
| Laan, RF | 4 |
| Barton, IP | 2 |
| Arai, T | 1 |
| Inoue, Y | 1 |
| Hayashi, S | 1 |
| Yamamoto, S | 1 |
| Sakatani, M | 1 |
| Tenenhouse, AM | 1 |
| Reszka, AA | 1 |
| Rodan, GA | 2 |
| McClung, M | 3 |
| O'Brien, FJ | 1 |
| Brennan, O | 1 |
| Kennedy, OD | 1 |
| Lee, TC | 1 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Heaney, RP | 2 |
| Valent, DJ | 1 |
| Jack, D | 1 |
| Nakahara, T | 1 |
| Nagai, N | 1 |
| Tanaka, M | 1 |
| Muranaga, T | 1 |
| Kojima, S | 1 |
| Nozoe, S | 1 |
| Naruo, T | 1 |
| Fleming, A | 1 |
| Sato, M | 1 |
| Goldsmith, P | 1 |
| Fujii, N | 1 |
| Hamano, T | 1 |
| Isaka, Y | 1 |
| Ito, T | 1 |
| Imai, E | 1 |
| Ijiri, S | 2 |
| Kouroukis, T | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Orcel, P | 2 |
| Dogru, T | 1 |
| Sonmez, A | 1 |
| Tasci, I | 1 |
| Genc, H | 1 |
| Henderson, S | 1 |
| Hoffman, N | 1 |
| Prince, R | 1 |
| Dobnig, H | 1 |
| Hofbauer, LC | 1 |
| Viereck, V | 1 |
| Obermayer-Pietsch, B | 1 |
| Fahrleitner-Pammer, A | 1 |
| Haas, M | 1 |
| Allison, J | 1 |
| Freeman, A | 2 |
| Kovac, SH | 1 |
| Doi, K | 1 |
| Takagi, C | 1 |
| Shigemoto, M | 1 |
| Morimoto, T | 1 |
| Corners, J | 1 |
| Naunton, M | 1 |
| Troen, BR | 1 |
| Allison, JJ | 1 |
| Neumaier, J | 1 |
| Downey, TW | 1 |
| Foltz, SH | 1 |
| Boccuzzi, SJ | 1 |
| Omar, MA | 1 |
| Kahler, KH | 1 |
| Buckland-Wright, JC | 1 |
| Messent, EA | 1 |
| Bingham, CO | 1 |
| Ward, RJ | 1 |
| Tonkin, C | 1 |
| Nishio, M | 1 |
| van der Geest, SA | 1 |
| Möller, G | 1 |
| Itabashi, A | 1 |
| Nawata, H | 1 |
| Adami, S | 5 |
| Isaia, G | 1 |
| Luisetto, G | 1 |
| Sinigaglia, L | 1 |
| Gentilella, R | 1 |
| Agnusdei, D | 1 |
| Iori, N | 1 |
| Cruse, LM | 1 |
| Valeriano, J | 1 |
| Vasey, FB | 1 |
| Carter, JD | 1 |
| Suzuki, Y | 2 |
| Bobba, RS | 1 |
| Beattie, K | 1 |
| Parkinson, B | 1 |
| Kumbhare, D | 1 |
| Shu, G | 1 |
| Nagashima, M | 2 |
| Lambrinoudaki, I | 1 |
| Christodoulakos, G | 1 |
| Botsis, D | 1 |
| Kaneda, K | 1 |
| Sakurai, M | 1 |
| Sugioka, Y | 1 |
| Inoue, A | 1 |
| Yamamoto, I | 1 |
| Hoshino, Y | 1 |
| Kawaguchi, H | 1 |
| Avorn, J | 1 |
| Finkelstein, JS | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Khosa, AD | 1 |
| Nayyar, MS | 1 |
| Beirne, JC | 1 |
| Seino, Y | 1 |
| Vlak, T | 1 |
| Dar Santos, AE | 1 |
| Kamatari, M | 1 |
| Koto, S | 1 |
| Ozawa, N | 1 |
| Urao, C | 1 |
| Akasaka, E | 1 |
| Yanagimoto, K | 1 |
| Sakota, K | 1 |
| Yamada, S | 1 |
| Takagi, H | 1 |
| Tsuchiya, H | 1 |
| Nakajima, T | 1 |
| Ochiai, H | 1 |
| Ichimura, A | 1 |
| Iwata, H | 1 |
| Toriyama, T | 1 |
| Yonehara, Y | 1 |
| Iwamoto, I | 1 |
| Kosha, S | 1 |
| Rai, Y | 1 |
| Sagara, Y | 1 |
| Douchi, T | 1 |
| Christodoulakos, GE | 1 |
| Mellström, D | 1 |
| Nickelsen, T | 1 |
| Pavo, I | 1 |
| Nakayama, H | 1 |
| Dalle Carbonare, L | 1 |
| Bertoldo, F | 1 |
| Valenti, MT | 1 |
| Zordan, S | 1 |
| Sella, S | 1 |
| Fassina, A | 1 |
| Turco, G | 1 |
| Realdi, G | 1 |
| Lo Cascio, V | 1 |
| Giannini, S | 1 |
| Ishizaka, K | 1 |
| Machida, T | 1 |
| Kanbe, N | 1 |
| Kitahara, S | 1 |
| Yoshida, K | 1 |
| Mok, CC | 1 |
| Tong, KH | 1 |
| To, CH | 1 |
| Siu, YP | 1 |
| Ma, KM | 1 |
| Bobba, R | 1 |
| Takada, T | 1 |
| Katsuki, Y | 1 |
| Kimura, N | 1 |
| Kaneko, Y | 1 |
| Ding, H | 1 |
| Koinuma, N | 1 |
| Stevenson, M | 1 |
| Monma, Y | 1 |
| Narusawa, K | 1 |
| Sosa Henríquez, M | 1 |
| Díaz Curiel, M | 1 |
| Díez Pérez, A | 1 |
| Gómez Alonso, C | 1 |
| González Macías, J | 1 |
| Farrerons Minguella, J | 1 |
| Filgueira Rubio, J | 1 |
| Mellibovsky Saidler, L | 1 |
| Nogués Solán, X | 1 |
| Hernández Hernández, D | 1 |
| Morishita, M | 1 |
| Wauke, K | 1 |
| Takahashi, H | 1 |
| Takenouchi, K | 1 |
| Satoh, T | 1 |
| Okazaki, M | 1 |
| Tabata, K | 1 |
| Tsuboi, T | 1 |
| Hyodo, T | 1 |
| Yokoyama, E | 1 |
| Matsumoto, K | 1 |
| Soh, S | 1 |
| Iwamura, M | 1 |
| Hayakawa, K | 1 |
| Bab, S | 1 |
| Oyoo, GO | 1 |
| Kariuki, JG | 1 |
| Liubchenko, PN | 1 |
| Dmiruk, LI | 1 |
| Fonin, OP | 1 |
| Nikolaeva, VV | 1 |
| Saratseva, VM | 1 |
| Liu, RH | 1 |
| Werth, VP | 1 |
| Ioachimescu, A | 1 |
| Licata, A | 1 |
| Gärtner, R | 1 |
| Moride, Y | 1 |
| Geller, JL | 1 |
| Hu, B | 2 |
| Reed, S | 1 |
| Mirocha, J | 1 |
| Adams, JS | 1 |
| Righi, G | 1 |
| Turchetti, V | 1 |
| Vattimo, A | 1 |
| Fogelman, I | 6 |
| Smith, ML | 2 |
| Nugent, CA | 1 |
| Gall, EP | 1 |
| Pitt, MJ | 1 |
| Schneider, VS | 2 |
| McDonald, J | 1 |
| Anderson, C | 1 |
| Cape, RD | 1 |
| Crilly, RG | 2 |
| Hodsman, AB | 3 |
| Wolfe, BM | 1 |
| Coakley, G | 1 |
| Isenberg, DA | 1 |
| Pilbeam, CC | 1 |
| Grant, SF | 1 |
| Lukert, BP | 1 |
| Struys, A | 1 |
| Snelder, AA | 1 |
| Mulder, H | 2 |
| Steiniche, T | 2 |
| Valero, MA | 1 |
| Loinaz, C | 1 |
| Larrodera, L | 1 |
| Leon, M | 1 |
| Moreno, E | 1 |
| Kemp, KB | 1 |
| Ryan, PJ | 1 |
| Cooper, C | 5 |
| Compston, J | 2 |
| Skingle, SJ | 1 |
| Crisp, AJ | 1 |
| Orme, SM | 1 |
| Simpson, M | 1 |
| Stewart, SP | 1 |
| Oldroyd, B | 1 |
| Westmacott, CF | 1 |
| Smith, MA | 1 |
| Belchetz, PE | 1 |
| Tovey, FI | 1 |
| Hall, ML | 1 |
| Ell, PJ | 1 |
| Hobsley, M | 1 |
| Worth, H | 1 |
| Stammen, D | 1 |
| Keck, E | 2 |
| Cormier, C | 1 |
| Leidig-Bruckner, G | 1 |
| Storm, T | 1 |
| Thamsborg, G | 1 |
| Bruckner, T | 1 |
| Sauer, P | 1 |
| Schilling, T | 1 |
| Soerensen, OH | 1 |
| Ziegler, R | 2 |
| Melton, ME | 1 |
| Kochman, ML | 1 |
| Hosie, G | 1 |
| Albert, S | 1 |
| Glynn, C | 1 |
| Odell, WD | 1 |
| Heath, H | 1 |
| Ongphiphadhanakul, B | 1 |
| Jenis, LG | 1 |
| Braverman, LE | 1 |
| Alex, S | 1 |
| Stein, GS | 1 |
| Lian, JB | 1 |
| Baran, DT | 2 |
| Seedor, JG | 1 |
| Balena, R | 1 |
| Frost, NA | 1 |
| Morand, EF | 1 |
| Hall, CL | 1 |
| Maddison, PJ | 1 |
| Bhalla, AK | 1 |
| Recker, RR | 1 |
| Greenspan, SL | 1 |
| Resnick, NM | 1 |
| Melsen, F | 1 |
| Daly, PA | 1 |
| Seeman, E | 2 |
| Tsalamandris, C | 1 |
| Bass, S | 1 |
| Pearce, G | 1 |
| Millard, PS | 1 |
| Van Cleemput, J | 1 |
| Daenen, W | 1 |
| Dequeker, P | 1 |
| Van De Werf, F | 1 |
| VanHaecke, J | 1 |
| Kowalchuk, RM | 1 |
| Corcoran, TA | 1 |
| Pollack, SR | 1 |
| Steinberg, ME | 2 |
| Kemink, SA | 1 |
| Smals, AG | 1 |
| Kloppenborg, PW | 1 |
| Paterson, AH | 1 |
| Powles, TJ | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Bensen, WG | 4 |
| Bianchi, F | 2 |
| Cividano, A | 1 |
| Craig, GL | 1 |
| Cranney, A | 1 |
| Kaminska, E | 2 |
| Gordon, M | 2 |
| Steele, M | 1 |
| Goldsmith, C | 1 |
| Papapoulos, SE | 3 |
| Lockefeer, JH | 2 |
| Patel, S | 1 |
| Wolfhagen, FH | 1 |
| van Buuren, HR | 1 |
| den Ouden, JW | 1 |
| Hop, WC | 1 |
| van Leeuwen, JP | 1 |
| Schalm, SW | 1 |
| Pols, HA | 1 |
| Fleisch, HA | 1 |
| Vanhoof, J | 2 |
| Raus, J | 2 |
| Dequeker, J | 3 |
| Nijs, J | 2 |
| Joly, J | 2 |
| Zamberlan, N | 1 |
| Castello, R | 1 |
| Gatti, D | 1 |
| Rossini, M | 1 |
| Braga, V | 1 |
| Fracassi, E | 1 |
| Jacobs, JW | 1 |
| Bijlsma, JW | 1 |
| van Veen, GJ | 1 |
| Houben, HH | 1 |
| Haanen, HC | 1 |
| Gerrits, MI | 1 |
| van Rijn, HJ | 1 |
| Hanley, D | 1 |
| Hodsman, A | 2 |
| Lentle, B | 2 |
| Olszynski, W | 1 |
| Chines, AA | 4 |
| Axelrod, DW | 1 |
| Rosen, C | 2 |
| Anderson, FH | 1 |
| Bishop, JC | 1 |
| Rawlings, DJ | 1 |
| Disla, E | 1 |
| Tamayo, B | 1 |
| Fahmy, A | 1 |
| Ma, YF | 1 |
| Pan, Z | 1 |
| Jee, WS | 1 |
| Lin, CH | 1 |
| Liang, HH | 1 |
| Chen, H | 1 |
| Pun, S | 1 |
| Li, XJ | 1 |
| van Staa, T | 1 |
| Abenhaim, L | 1 |
| Fairney, A | 1 |
| Kyd, P | 1 |
| Thomas, E | 1 |
| Wilson, J | 1 |
| Oriente, P | 1 |
| Laan, R | 1 |
| Hughes, RA | 3 |
| Ittner, J | 1 |
| Di Munno, O | 1 |
| Pouillès, JM | 1 |
| Horlait, S | 1 |
| MacInnis, C | 1 |
| Boyle, IT | 1 |
| Purdie, DW | 1 |
| Ralston, S | 1 |
| Reeve, J | 2 |
| Stevenson, JC | 1 |
| Masson, C | 1 |
| Audran, M | 2 |
| Pascaretti, C | 1 |
| Namour, A | 1 |
| Saumet, JL | 1 |
| Baslé, MF | 2 |
| Legrand, E | 2 |
| Bregeon, C | 1 |
| Renier, JC | 1 |
| Cowan, S | 1 |
| Morin, S | 1 |
| Ernst, P | 1 |
| Pitt, P | 1 |
| Li, F | 1 |
| Todd, P | 1 |
| Webber, D | 1 |
| Pack, S | 3 |
| Moniz, C | 2 |
| Ylitalo, R | 1 |
| Kalliovalkama, J | 1 |
| Wu, X | 1 |
| Kankaanranta, H | 1 |
| Salenius, JP | 1 |
| Sisto, T | 1 |
| Lähteenmäki, T | 1 |
| Ylitalo, P | 1 |
| Pörsti, I | 1 |
| Gennari, C | 1 |
| Shane, E | 1 |
| Rodino, MA | 1 |
| Addesso, V | 1 |
| Staron, RB | 1 |
| Mancini, D | 1 |
| Michler, RE | 1 |
| Lo, SH | 1 |
| Millson, D | 1 |
| Clark, W | 1 |
| Thomas, T | 1 |
| Barou, O | 1 |
| Vico, L | 2 |
| Alexandre, C | 4 |
| Lafage-Proust, MH | 1 |
| Stalmans, R | 1 |
| Li, QN | 1 |
| Liang, NC | 1 |
| Huang, LF | 1 |
| Wu, T | 1 |
| Mo, LE | 1 |
| Hachulla, E | 1 |
| Bonvoisin, B | 1 |
| Compston, JE | 1 |
| Jenkins, EA | 2 |
| Walker-Bone, KE | 2 |
| Wood, A | 1 |
| McCrae, FC | 1 |
| Cawley, MI | 2 |
| Cividino, A | 1 |
| Scocchia, T | 1 |
| Stephenson, GF | 4 |
| Ullom-Minnich, P | 1 |
| Dunlop, MB | 1 |
| Lane, NE | 1 |
| Hamdy, RC | 1 |
| Goldstein, MF | 1 |
| Fallon, JJ | 1 |
| Harning, R | 1 |
| Cook, GJ | 1 |
| Kessenich, CR | 1 |
| Sacco-Gibson, NA | 1 |
| Wenderoth, DH | 1 |
| Eusebio, RA | 1 |
| Levin, E | 1 |
| Helfgott, SM | 1 |
| Soucy, E | 1 |
| Bellamy, N | 1 |
| Pope, JE | 1 |
| Flynn, J | 1 |
| Sutton, E | 1 |
| Campbell, J | 1 |
| Rodionova, SS | 2 |
| Kolondaev, AF | 1 |
| Matkovskaia, TA | 1 |
| MacGowan, JR | 1 |
| Pringle, J | 1 |
| Morris, VH | 1 |
| Stamp, TC | 1 |
| Hunziker, J | 1 |
| Wronski, TJ | 2 |
| Miller, SC | 1 |
| Elkayam, O | 1 |
| Paran, D | 1 |
| Yaron, M | 1 |
| Caspi, D | 1 |
| Peel, NF | 1 |
| Bax, DE | 1 |
| Sacco-Gibson, N | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Leder, BZ | 1 |
| Kronenberg, HM | 1 |
| Wallach, S | 1 |
| Cohen, S | 1 |
| Doherty, SM | 1 |
| Pitt, PI | 1 |
| Jinnouchi, Y | 1 |
| Mackey, MS | 1 |
| Hamburg, SM | 1 |
| Piers, DA | 1 |
| van den Berg, AP | 1 |
| Slooff, MJ | 1 |
| Haagsma, EB | 1 |
| Olszynski, WO | 1 |
| Chapurlat, R | 1 |
| Lindor, KD | 1 |
| Jorgensen, RA | 1 |
| Tiegs, RD | 1 |
| Khosla, S | 1 |
| Dickson, ER | 1 |
| Macedo, G | 1 |
| Azevedo, F | 1 |
| Ribeiro, T | 1 |
| Crandall, C | 1 |
| Henderson, K | 1 |
| Eisman, J | 1 |
| Keogh, A | 1 |
| MacDonald, P | 1 |
| Glanville, A | 1 |
| Spratt, P | 1 |
| Arlen, DJ | 1 |
| Lambert, K | 1 |
| Price, PA | 1 |
| Faus, SA | 1 |
| Williamson, MK | 1 |
| Vasseur, J | 1 |
| Grardel, B | 1 |
| Catanzariti, L | 1 |
| Marchandise, X | 1 |
| Delcambre, B | 1 |
| Chapurlat, RD | 1 |
| Cefalu, CA | 1 |
| Ettinger, B | 1 |
| Chidambaran, P | 1 |
| Pressman, A | 1 |
| Kauffman, RP | 1 |
| Overton, TH | 1 |
| Shiflett, M | 1 |
| Jennings, JC | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| McClung, B | 1 |
| LeBlanc, A | 1 |
| Huntoon, CL | 1 |
| Turner, CH | 1 |
| Forwood, MR | 1 |
| Jacob, DS | 1 |
| Peters, ML | 1 |
| Leonard, M | 1 |
| Rovati, LC | 1 |
| Anastassiades, TP | 1 |
| Hanly, JG | 1 |
| Jovaisas, A | 1 |
| Chines, A | 1 |
| Dias, R | 1 |
| Katsumata, T | 1 |
| Tanaka, T | 1 |
| Ichimura, S | 1 |
| Toyama, Y | 1 |
| Caulfield, T | 1 |
| Bolognese, MA | 1 |
| Lindsay, R | 1 |
| Roberts, A | 1 |
| Zippel, H | 1 |
| Ernst, TF | 1 |
| Stevens, KP | 1 |
| Dougherty, JA | 1 |
| Qureshi, AM | 1 |
| Herd, RJ | 1 |
| Bannwarth, B | 1 |
| Hayashi, Y | 1 |
| Ishii, J | 1 |
| Atoyebi, W | 1 |
| Brown, M | 1 |
| Wass, J | 1 |
| Littlewood, TJ | 1 |
| Hatton, C | 1 |
| Moreau, MF | 1 |
| Roll, KT | 1 |
| Chapuy, MC | 1 |
| Meunier, P | 1 |
| Fleisch, H | 2 |
| Lauffenburger, T | 1 |
| Olah, AJ | 1 |
| Dambacher, MA | 1 |
| Guncaga, J | 1 |
| Lentner, C | 1 |
| Haas, HG | 1 |
| Kuska, J | 1 |
| Saville, PD | 1 |
| Ambrus, JL | 1 |
| Hoffman, M | 1 |
| Ambrus, CM | 1 |
| Hreshchyshyn, MM | 1 |
| Moore, D | 1 |
| Munschauer, FE | 1 |
| Warneke, G | 1 |
| Henning, HV | 1 |
| Kasting, GB | 1 |
| Francis, MD | 1 |
| Pallot-Prades, B | 1 |
| Tavan, P | 1 |
| Prallet, B | 1 |
| Riffat, G | 2 |
| Papapoulos, S | 1 |
| Horowitz, E | 1 |
| Miller, JL | 1 |
| Rose, LI | 1 |
| Togari, A | 1 |
| Arai, M | 1 |
| Hironaka, M | 1 |
| Matsumoto, S | 1 |
| Shinoda, H | 1 |
| Ullrich, I | 1 |
| Hart, DM | 1 |
| Scott, E | 1 |
| Bevan, J | 1 |
| Leggate, I | 1 |
| Mallette, LE | 1 |
| LeBlanc, AD | 1 |
| Pool, JL | 1 |
| Mechanick, JI | 1 |
| Trzenschik, K | 1 |
| Lindenhayn, K | 1 |
| Bühler, G | 1 |
| Delling, G | 2 |
| Dreyer, T | 1 |
| Vogel, M | 1 |
| Hahn, M | 1 |
| Rittinghaus, EF | 2 |
| Hesch, RD | 2 |
| Dann, LM | 1 |
| Scott, KS | 1 |
| Crooke, LR | 1 |
| Palle, S | 1 |
| Morukov, BV | 1 |
| Minaire, P | 1 |
| Pacifici, R | 1 |
| McMurtry, C | 1 |
| Vered, I | 1 |
| Rupich, R | 1 |
| Avioli, LV | 1 |
| Heck, J | 1 |
| Canzler, H | 1 |
| Schober, O | 1 |
| Harms, H | 1 |
| Shiota, E | 1 |
| Lane, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| International Breast Cancer Intervention Study[NCT00078832] | Phase 3 | 3,864 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study[NCT03401619] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2017-09-21 | Active, not recruiting | |||
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma[NCT00054418] | Phase 3 | 216 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis[NCT00100620] | Phase 3 | 802 participants | Interventional | 2004-06-30 | Completed | ||
| Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial[NCT04034199] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-08-15 | Not yet recruiting | ||
| Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study[NCT00043069] | Phase 3 | 71 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study[NCT00619957] | Phase 3 | 285 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis[NCT01611571] | Phase 3 | 31 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men[NCT00503399] | Phase 3 | 92 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| The Pharmacokinetics and Pharmacodynamics Study of Intravenous Zoledronic Acid in Chinese Subjects With Low Bone Mass or Osteoporosis: a Randomized Placebo-controlled Trail[NCT04719650] | Phase 4 | 64 participants (Anticipated) | Interventional | 2021-10-31 | Not yet recruiting | ||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516] | Phase 4 | 26 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | millimeters (Least Squares Mean) |
|---|---|
| Placebo | -2.39 |
| Risedronate | -2.68 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | millimeters (Least Squares Mean) |
|---|---|
| Placebo | -0.77 |
| Risedronate | -0.92 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | millimeters (Least Squares Mean) |
|---|---|
| Placebo | -2.66 |
| Risedronate | -3.13 |
Kaplan-Meier Cumulative Incidence, fractures / 100 patients / year (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Fractures / 100 patients / year (Number) |
|---|---|
| Placebo | 3.4 |
| Risedronate | 2.7 |
Kaplan-Meier Cumulative Incidence, fractures / 100 patients / 2 years (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Fractures / 100 patients / 2 years (Number) |
|---|---|
| Placebo | 7.7 |
| Risedronate | 4.9 |
(NCT00619957)
Timeframe: Baseline to Month 3
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | -8.89 |
| Risedronate | -24.53 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.99 |
| Risedronate | -25.27 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -7.11 |
| Risedronate | -29.51 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 2.95 |
| Risedronate | -25.20 |
(NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -8.68 |
| Risedronate | -29.78 |
(NCT00619957)
Timeframe: Baseline to Month 3
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -14.56 |
| Risedronate | -58.16 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 6.39 |
| Risedronate | -38.76 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -19.12 |
| Risedronate | -61.46 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 9.28 |
| Risedronate | -37.27 |
(NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -13.72 |
| Risedronate | -58.44 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.53 |
| Risedronate | 1.59 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.62 |
| Risedronate | 1.49 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.42 |
| Risedronate | 1.65 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic Reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.48 |
| Risedronate | 0.98 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.57 |
| Risedronate | 2.73 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.81 |
| Risedronate | 1.89 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.52 |
| Risedronate | 2.83 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.67 |
| Risedronate | 1.24 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.42 |
| Risedronate | 4.60 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Mean of 2 scans performed. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.40 |
| Risedronate | 5.98 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading.DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.03 |
| Risedronate | 3.60 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Site will perform at screening to determine if scan should be forwarded to central facility for analysis. Mean of 2 scans performed read by central lab to determine entry qualification. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.22 |
| Risedronate | 5.75 |
(NCT00619957)
Timeframe: Baseline to Month 3
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -17.41 |
| Risedronate | -33.28 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -20.45 |
| Risedronate | -36.82 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -16.46 |
| Risedronate | -38.42 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -22.27 |
| Risedronate | -37.38 |
(NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -7.98 |
| Risedronate | -29.97 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.24 |
| Risedronate | 1.71 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.74 |
| Risedronate | 1.38 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.06 |
| Risedronate | 1.76 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.76 |
| Risedronate | 1.16 |
responder = positive change (>0) in lumbar spine BMD from Baseline to Month 24 (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 60.3 |
| Risedronate | 89.5 |
Change in the Femoral Neck BMD at 18 month (NCT01611571)
Timeframe: 18 months
| Intervention | % change in TH BMD (Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 8.45 |
| Active Risedronte Placebo Teriparatide | 0.5 |
| Placebo Risedronate Active Teriparatide | 3.89 |
change in 1/3 radius of forearm bone density as measured by DXA (NCT01611571)
Timeframe: baseline and 18 months
| Intervention | % change in 1/3 Radius BMD (Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 1.6 |
| Active Risedronte Placebo Teriparatide | 0.11 |
| Placebo Risedronate Active Teriparatide | 0.02 |
change in hip bone density measured by DXA (NCT01611571)
Timeframe: baseline and 18 months
| Intervention | % change in TH BMD (Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 3.86 |
| Active Risedronte Placebo Teriparatide | 0.82 |
| Placebo Risedronate Active Teriparatide | 0.29 |
change in spine bone density at 18 months measured by DXA 18 and 24 months (NCT01611571)
Timeframe: 18 months
| Intervention | % change in LS BMD (Least Squares Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 6.95 |
| Active Risedronte Placebo Teriparatide | 3.76 |
| Placebo Risedronate Active Teriparatide | 5.68 |
counting the total new morphometric vertebral fractures as determined by x-ray from baseline through end of study (NCT01611571)
Timeframe: baseline through 18 months
| Intervention | vertebral fracture (Number) |
|---|---|
| Active Risedronate Active Teriparatide | 1 |
| Active Risedronte Placebo Teriparatide | 1 |
| Placebo Risedronate Active Teriparatide | 0 |
Least Squares (LS) Means were adjusted for age, baseline propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) |
|---|---|
| Teriparatide | 4.31 |
| Risedronate | 2.52 |
Least Squares (LS) Means were adjusted for age, baseline serum aminoterminal propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 18 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) |
|---|---|
| Teriparatide | 12.28 |
| Risedronate | 2.94 |
Anterior bending and axial torsion were measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | Newton/millimeter/radian (N/mm/rad) (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anterior bending stiffness at 6 months | Anterior bending stiffness at 18 months | Axial torsion stiffness at 6 months | Axial torsion stiffness at 18 months | Anterior bending strength at 6 months | Anterior bending strength at 18 months | Axial torsion strength at 6 months | Axial torsion strength at 18 months | |
| Risedronate | 415705.0 | 233283.0 | 77830.7 | 56639.3 | 8827.2 | 4822.0 | 3664.0 | 2545.8 |
| Teriparatide | 664969.0 | 1209225.0 | 142902.9 | 279392.8 | 12490.9 | 26046.4 | 6127.7 | 14181.3 |
Dual x-ray absorptiometry (DXA) techniques validated this measurement at skeletal sites that are at risk of osteoporotic fracture, such as lumbar spine, femoral neck, and hip. (NCT00503399)
Timeframe: Baseline, 18 months
| Intervention | grams per square centimeter (g/cm^2) (Mean) | ||
|---|---|---|---|
| Lumbar spine (n=38; n=39) | Hip (n=38; n=37) | Femoral neck (n=38; n=37) | |
| Risedronate | 0.037 | 0.007 | -0.007 |
| Teriparatide | 0.068 | 0.014 | 0.014 |
Axial compression was measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated the strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | Newton per millimeter (N/mm) (Least Squares Mean) | |||
|---|---|---|---|---|
| Axial compression stiffness at 6 months | Axial compression stiffness at 18 months | Axial compression strength at 6 months | Axial compression strength at 18 months | |
| Risedronate | 407.6 | 363.7 | 313.6 | 209.4 |
| Teriparatide | 890.7 | 1973.9 | 580.7 | 1287.5 |
Three-dimensional (3-D) microstructure variables of T12 were assessed by HR-QCT. In contrast with regular QCT that assessed 3 millimeter (mm) slide thickness, HR-QCT used segmentation of 1 single vertebra with approximately 100 consecutive slides reconstructed at 300-400 micrometer (µm) slice increments covering the complete vertebral body. Least Squares (LS) Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) | |||
|---|---|---|---|---|
| Integral BMD at 6 months | Integral BMD at 18 months | Trabecular BMD at 6 months | Trabecular BMD at 18 months | |
| Risedronate | -1.91 | 0.68 | -0.87 | 0.22 |
| Teriparatide | -0.42 | 10.72 | -0.70 | 9.53 |
P1NP was used as a serum biochemical marker of collagen synthesis, reflecting the formation of new osteoid. (NCT00503399)
Timeframe: Baseline, 3 months, 6 months, 18 months
| Intervention | micrograms per deciliter (μg/dL) (Least Squares Mean) | ||
|---|---|---|---|
| P1NP at 3 months | P1NP at 6 months | P1NP at 18 months | |
| Risedronate | -16.09 | -16.50 | -15.58 |
| Teriparatide | 27.33 | 52.55 | 28.48 |
β-CTx was used as a biochemical marker of bone turnover/resorption, reflecting collagen breakdown of the bone matrix. (NCT00503399)
Timeframe: 3, 6, 18 months
| Intervention | nanograms per deciliter (ng/dL) (Least Squares Mean) | ||
|---|---|---|---|
| β-CTx at 3 months | β-CTx at 6 months | β-CTx at 18 months | |
| Risedronate | -0.15 | -0.14 | -0.11 |
| Teriparatide | 0.12 | 0.25 | 0.03 |
Summary tables of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module. Fractures that occurred during the study were collected separately as an additional safety variable. The number of participants experiencing hypercalcemia was summarized for each treatment arm. Hypercalcemia was defined as a serum calcium level corrected for albumin of >2.7 millimole per liter (mmol/L) (10.8 milligram per deciliter [mg/dL]). (NCT00503399)
Timeframe: Baseline up to 18 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Serious Adverse Events (SAEs) | Other Non-serious AEs | Fractures | Hypercalcemia | |
| Risedronate | 22 | 30 | 5 | 0 |
| Teriparatide | 13 | 22 | 0 | 0 |
BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | grams/centimeters squared (g/cm^2) (Mean) | |||
|---|---|---|---|---|
| Spine, Baseline | Spine, Change from Baseline at Month12 | Femoral neck, Baseline | Femoral neck, Change from Baseline at Month 12 | |
| Control Arm | 0.93 | -0.002 | 0.73 | -0.03 |
| Teriparatide | 0.91 | 0.06 | 0.68 | 0.03 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 2.73 | -0.50 |
| Teriparatide | 2.66 | 0.42 |
Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | cubic millimeter (mm^3) (Median) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 571.4 | 9.1 |
| Teriparatide | 369.8 | -0.4 |
139 reviews available for etidronate and Osteoporosis
| Article | Year |
|---|---|
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Et | 2022 |
Comparing the Efficacies of Bisphosphonates' Therapies for Osteoporosis Persistence and Compliance: A Systematic Review.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; | 2022 |
[Dynamics of bone resorption analyzed by intravital imaging].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; | 2013 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservati | 2014 |
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations | 2008 |
[Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Fractures, | 2008 |
[Evidence and utility of etidronate for the treatment of osteoporosis].
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fem | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Admini | 2009 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometall | 2009 |
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Follow | 2009 |
[Risedronate for treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spont | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosph | 2009 |
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2010 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceut | 2009 |
Challenges in clinical patient management.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etid | 2010 |
[Dementia and fracture].
Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism | 2010 |
Treatments for osteoporosis in people with a disability.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Disabled Persons; Etidronic Acid; Hu | 2011 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Iband | 2011 |
Risedronate-associated scleritis: a case report and review of the literature.
Topics: Adrenal Cortex Hormones; Aged; Brain; China; Diphosphonates; Etidronic Acid; Female; Humans; Inflamm | 2012 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Osteoporosis: diagnosis and treatment of vertebral fractures].
Topics: Age Factors; Aged; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Middle A | 2002 |
Editorial: greater risk, greater benefit--true or false?
Topics: Calcium Channel Blockers; Etidronic Acid; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk | 2003 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; | 2002 |
[Etidronate].
Topics: Etidronic Acid; Female; Humans; Osteoporosis | 2003 |
[Risedronate].
Topics: Aged; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
Prevention and treatment of osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Calcium; Dietary Supplements; Estrogen Replacement Therapy; Etidronic | 2002 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Os | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
An update on bisphosphonates.
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Hum | 2004 |
What predicts early fracture or bone loss on bisphosphonate therapy?
Topics: Alendronate; Etidronic Acid; Female; Forecasting; Fractures, Bone; Humans; Middle Aged; Osteoporosis | 2003 |
[Bone mass measurement and evaluation of therapeutical response].
Topics: Absorptiometry, Photon; Aging; Alendronate; Biomarkers; Bone Density; Calcium; Estrogen Replacement | 2004 |
[AOS-100].
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Etidronic Acid; Humans; Mass Screening; Osteoporo | 2004 |
[New guideline for the treatment of osteoporosis].
Topics: Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medic | 2004 |
[Treatment of osteoporosis with etidronate].
Topics: Adenosine Triphosphate; Arthralgia; Bone Density; Clinical Trials as Topic; Energy Metabolism; Etidr | 2004 |
[Risedronate treatment for osteoporosis].
Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fra | 2004 |
[VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study].
Topics: Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteo | 2004 |
[Treatment of osteoporosis combined with a bisphosphonate and vitamin D3].
Topics: Alendronate; Bone Density; Cholecalciferol; Drug Therapy, Combination; Etidronic Acid; Humans; Multi | 2004 |
[Concurrent treatment of osteoporosis with bisphosphonate and vitamin K2].
Topics: Animals; Bone Density; Bone Resorption; Drug Therapy, Combination; Etidronic Acid; Humans; Osteoporo | 2004 |
[Combination therapy of bisphosphonate and estrogen for osteoporosis].
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Fem | 2004 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Algorithms; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteop | 2004 |
Fracture protection in osteoporosis with risedronate.
Topics: Aged; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Ag | 2004 |
[Bone quality in treatment with raroxifene ].
Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C | 2005 |
[Effects of concurrent therapy for patients with osteoporosis].
Topics: Aged; Bone Density; Cholecalciferol; Clinical Trials as Topic; Diphosphonates; Drug Therapy, Combina | 2005 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle | 2005 |
Mechanism of action of bisphosphonates.
Topics: Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; Sensitivity a | 2003 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu | 2005 |
Microcracks in cortical bone: how do they affect bone biology?
Topics: Animals; Bone and Bones; Bone Matrix; Bone Remodeling; Calcium Channel Blockers; Etidronic Acid; Fra | 2005 |
Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Huma | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; | 2006 |
[Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Hydroxych | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandroni | 2006 |
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporo | 2007 |
[Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postme | 2006 |
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteop | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
[Concurrent treatment of osteoporosis including vitamin K].
Topics: Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Drug Therapy, Combi | 2007 |
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fractures, | 2007 |
[Bisphosphonates for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Diphosphonates; Etidronic Acid; Ev | 2007 |
[Evidence of risedronate for treatment of osteoporosis].
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Evidenc | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
Osteoporosis--from hormonal replacement therapy to bisphosphonates and beyond: a review.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Hormone R | 2007 |
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Conf | 2008 |
Etidronate: what is its place in treatment of primary osteoporosis and other demineralizing diseases today?
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Humans; Osteoporosi | 2007 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Treatment of osteoporosis.
Topics: Adult; Aged; Bone Resorption; Calcitonin; Calcium, Dietary; Combined Modality Therapy; Estrogen Repl | 1995 |
What's new in osteoporosis?
Topics: Bone Density; Environmental Exposure; Etidronic Acid; Humans; Osteoporosis; Polymorphism, Genetic; R | 1995 |
Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
Topics: Adult; Aged; Aging; Benzothiadiazines; Bone and Bones; Calcium; Diuretics; Estrogens; Etidronic Acid | 1995 |
Corticosteroid-induced osteoporosis.
Topics: Bone Density; Calcitonin; Calcitriol; Calcium; Etidronic Acid; Humans; Osteoporosis; Prednisone; Ran | 1994 |
Epidemiology, diagnosis, and treatment of osteoporosis.
Topics: Aged; Bone and Bones; Bone Density; Bone Development; Etidronic Acid; Female; Fluorides; Fractures, | 1994 |
Osteoporosis: pathophysiology, prevention, diagnosis, and treatment.
Topics: Bone Density; Calcitriol; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic Acid; Exercise; | 1993 |
Preclinical pharmacology of alendronate.
Topics: Alendronate; Animals; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Estrogens; | 1993 |
Idiopathic polymyositis complicated by arthritis and mesangial proliferative glomerulonephritis: case report and review of the literature.
Topics: Arthritis; Etidronic Acid; Glomerulonephritis, Membranoproliferative; Humans; Male; Middle Aged; Ost | 1993 |
Clinical review 41: Current therapy for osteoporosis.
Topics: Calcitonin; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Fluori | 1993 |
Office management of osteoporosis: a guide for the primary care provider.
Topics: Adolescent; Adult; Aged; Calcitonin; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic Acid; | 1995 |
Present and future of osteoporosis therapy.
Topics: Bone Density; Bone Development; Bone Resorption; Calcitonin; Calcitriol; Calcium, Dietary; Diphospho | 1995 |
[Bisphosphonates in osteoporosis; a reevaluation].
Topics: Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Humans; Osteoporosis | 1996 |
Current and potential future drug treatments for osteoporosis.
Topics: Aged; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Male; Middl | 1996 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteo | 1997 |
Pathogenesis of the osteoporoses.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Female; Humans; Middle Aged; Osteocla | 1997 |
Bisphosphonates in the treatment of osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 1997 |
Osteoporosis: trials and tribulations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Estrogen Replaceme | 1997 |
Management of male osteoporosis: report of the UK Consensus Group.
Topics: Adult; Aged; Aged, 80 and over; Alcoholism; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; | 1998 |
Further vascular, bone and autonomic investigations in algodystrophy.
Topics: Absorptiometry, Photon; Autonomic Nervous System; Autonomic Nervous System Diseases; Blood Vessels; | 1998 |
[Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Topics: Diphosphonates; Etidronic Acid; Humans; Osteoclasts; Osteoporosis | 1998 |
Bisphosphonates and osteoporosis treatment in Italy.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 1998 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; | 1999 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supp | 1999 |
Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease.
Topics: Administration, Inhalation; Administration, Oral; Adult; Alendronate; Asthma; Bone Density; Bone Rem | 1999 |
Etridronate therapy in the treatment and prevention of osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Osteop | 2000 |
Risedronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Adrenal Cortex Hormones; Aged; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporos | 2000 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Anabolic Agents; Bone Density; Calcitriol; Calcium; Estrogen Replacement Therapy; Etidr | 2000 |
[The potentials for using xidifon in diseases of the locomotor system].
Topics: Diphosphonates; Etidronic Acid; Humans; Musculoskeletal Diseases; Osteitis Deformans; Osteoporosis; | 2000 |
[Corticosteroid-induced osteoporosis-- prevention and treatment].
Topics: Adrenal Cortex Hormones; Calcitonin; Etidronic Acid; Female; Humans; Male; Osteoporosis; Vitamin D | 1999 |
Prevention and treatment of osteoporosis.
Topics: Accidental Falls; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium Chan | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Oste | 2000 |
A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Double-Blind Method; Drug Administration Schedule; Eti | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen R | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calci | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F | 2001 |
Risedronate: clinical usage.
Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei | 2001 |
Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.
Topics: Adolescent; Calcium Channel Blockers; Calcium, Dietary; Diagnosis, Differential; Etidronic Acid; Fem | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid | 2001 |
Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.
Topics: Alendronate; Bone and Bones; Bone Density; Climacteric; Drug Therapy, Combination; Etidronic Acid; F | 2001 |
Review of risedronate in the treatment of osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Pos | 2001 |
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clinical Trials, Phase III as | 2002 |
Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Mal | 2002 |
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; | 2002 |
[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
Topics: Alendronate; Calcitonin; Clinical Trials as Topic; Drug Approval; Estriol; Etidronic Acid; Europe; H | 2002 |
[Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Topics: Alendronate; Bone Density; Bone Remodeling; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 2002 |
[Risedronate: clinical usage].
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; H | 2002 |
Bone quality: getting closer to a definition.
Topics: Animals; Bone Density; Etidronic Acid; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Risedron | 2002 |
Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects.
Topics: Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcinosis; Calcium; Calcium M | 1975 |
[Diagnosis and treatment of osteoporosis].
Topics: Age Factors; Aged; Calcitonin; Calcium; Etidronic Acid; Exercise Therapy; Female; Fluorine; Humans; | 1975 |
Prevention and treatment of osteoporosis. One of the most frequent disorders in American women: a review.
Topics: Calcitonin; Calcium; Estrogens; Etidronic Acid; Female; Humans; Osteoporosis; Sodium Fluoride | 1992 |
[Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism].
Topics: Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Oste | 1992 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1991 |
[Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
Topics: Aged; Bone Density; Calcitonin; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combinat | 1991 |
Etidronate for hypercalcemia of malignancy and osteoporosis.
Topics: Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Ossification, Heterotopic; Osteitis Deformans; Ost | 1991 |
Therapies for symptomatic primary osteoporosis.
Topics: Aged; Calcitonin; Diagnosis, Differential; Etidronic Acid; Female; Humans; Male; Osteoporosis; Sodiu | 1991 |
Osteoporosis.
Topics: Aged; Androgens; Calcium, Dietary; Etidronic Acid; Female; Fluorides; Humans; Middle Aged; Osteoporo | 1991 |
New treatments for osteoporosis.
Topics: Bone Density; Bone Development; Bone Resorption; Drug Administration Schedule; Etidronic Acid; Femal | 1990 |
[Biphosphonate as a therapeutic drug--experimental studies and clinical application].
Topics: Animals; Calcinosis; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperpar | 1985 |
107 trials available for etidronate and Osteoporosis
| Article | Year |
|---|---|
Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2022 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; E | 2013 |
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Cons | 2013 |
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Glome | 2014 |
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation | 2013 |
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response Relati | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
[Comparative analysis of programs of complete correction osteogenic in patients with chronic pancreatitis].
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; M | 2014 |
Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.
Topics: Aged; Arteries; Biomarkers; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; D | 2008 |
Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Anticonvulsants; Benzodiazepines; Biomarke | 2008 |
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Aci | 2009 |
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neo | 2009 |
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Topics: Aged; Asian People; Back Pain; Body Height; Bone Density; Bone Density Conservation Agents; Bone Rem | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Double-Blind | 2010 |
Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Drug Administration S | 2010 |
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2010 |
Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Topics: Aged; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female | 2010 |
Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Clinical Protocols; Co | 2009 |
RETRACTED: Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke.
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Calcium; Chronic Disease; Dis | 2010 |
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Epidemiologic | 2010 |
Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; | 2011 |
Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Hydroxycholec | 2010 |
Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antineoplastic Age | 2011 |
Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Female; Humans; Knee | 2011 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalci | 2011 |
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bone Density; Bone Density Conservation Agents; Etidroni | 2011 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen | 2011 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone De | 2012 |
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosph | 2012 |
Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Ch | 2012 |
Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2012 |
Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic A | 2012 |
Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Topics: Bone Density; Bone Density Conservation Agents; Demography; Double-Blind Method; Etidronic Acid; Fem | 2012 |
Combination therapy with risedronate and teriparatide in male osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2013 |
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle | 2013 |
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Cons | 2013 |
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Euro | 2013 |
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2013 |
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Topics: Adult; Aged; Biomarkers; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid | 2002 |
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calci | 2003 |
Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty.
Topics: Aged; Analysis of Variance; Arthroplasty, Replacement, Hip; Biomarkers; Chi-Square Distribution; Dru | 2003 |
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
Topics: Administration, Oral; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administr | 2003 |
Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
Topics: Adult; Bone Density; Calcium Compounds; Connective Tissue Diseases; Drug Administration Schedule; Dr | 2003 |
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteopo | 2004 |
Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
Topics: Administration, Oral; Adult; Area Under Curve; Calcium Channel Blockers; Dose-Response Relationship, | 2004 |
Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.
Topics: Administration, Oral; Adult; Calcium Channel Blockers; Cross-Over Studies; Drug Administration Sched | 2004 |
Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.
Topics: Administration, Inhalation; Administration, Oral; Asthma; Bone Density; Calcium; Etidronic Acid; Fem | 2004 |
Etidronate and glucocorticoid induced osteoporosis.
Topics: Asthma; Bone Density; Budesonide; Drug Therapy, Combination; Etidronic Acid; Glucocorticoids; Humans | 2005 |
Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Bone and Bones; C-Reactive Protein; Cross-Linking Reage | 2004 |
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Bone Density; Calcium; Crohn Disease; Dose-Resp | 2005 |
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Do | 2004 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Double-Blind Method | 2005 |
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Fractures, | 2006 |
The effects of bone therapy on tibial bone loss in young women with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Humans; | 2006 |
A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; | 2006 |
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remo | 2006 |
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Di | 2006 |
[A head-to-head comparative study for evaluation of effectiveness among drugs for osteoporosis].
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Evaluation; | 2006 |
A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Disease Progression; Dose-Response Relationship, Drug | 2007 |
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Bli | 2006 |
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Adminis | 2006 |
Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Creatinine; Double-Blind Method; | 2007 |
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bo | 2007 |
Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation | 2007 |
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Bone Density Conservation Agents; Etidroni | 2007 |
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Topics: Adipose Tissue; Adult; Aged; Anti-Inflammatory Agents; Body Mass Index; Bone Density; Bone Density C | 2008 |
Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
Topics: Adrenal Cortex Hormones; Adult; Bone Density; Bone Density Conservation Agents; Connective Tissue Di | 2008 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; C | 2008 |
Efficacy of risedronate in Japanese male patients with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conse | 2008 |
Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Bone Density; Calcium; Drug Administration Sched | 1995 |
Calcitonin and bisphosphonates treatment in bone loss after liver transplantation.
Topics: Adult; Bone Density; Bone Diseases, Metabolic; Calcitonin; Etidronic Acid; Female; Humans; Liver Tra | 1995 |
Clinical experience with etidronate in osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Femur | 1994 |
Increased bone density in patients on steroids with etidronate.
Topics: Aged; Bone Density; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Prednisolone | 1994 |
Cyclical etidronate therapy and postgastrectomy osteoporosis.
Topics: Aged; Bone Density; Etidronic Acid; Gastrectomy; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteop | 1994 |
Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate.
Topics: Adrenal Cortex Hormones; Asthma; Bone Density; Calcium; Drug Therapy, Combination; Etidronic Acid; F | 1994 |
Comparison of a semiquantitative and a quantitative method for assessing vertebral fractures in osteoporosis.
Topics: Etidronic Acid; Female; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Randomized Controlled T | 1994 |
Corticosteroid-induced bone loss.
Topics: Calcium; Etidronic Acid; Female; Femur; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Age | 1996 |
Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D.
Topics: Calcium; Etidronic Acid; Heart Transplantation; Humans; Hydroxycholecalciferols; Middle Aged; Osteop | 1996 |
Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up.
Topics: Adrenal Cortex Hormones; Bone Density; Cohort Studies; Drug Administration Schedule; Etidronic Acid; | 1996 |
Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Bone Density; Double-Blind Method; Etidronic Acid; Female; Hum | 1997 |
Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
Topics: Adult; Anthropometry; Bone Density; Calcium; Drug Therapy, Combination; Etidronic Acid; Female; Hirs | 1997 |
Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
Topics: Adult; Aged; Bone Density; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combinat | 1997 |
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Calcium Carbonate; Double-Blind Method; Drug Administr | 1997 |
The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Remodeling; Calcium; Etidronic Acid; Female; Humans; | 1998 |
Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
Topics: Adrenal Cortex Hormones; Adult; Aged; Analysis of Variance; Bone Density; Double-Blind Method; Drug | 1998 |
A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
Topics: Aged; Asthma; Bone Density; Calcium; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; | 1998 |
Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
Topics: Aged; Analysis of Variance; Arthritis, Rheumatoid; Bone Density; Calcium; Double-Blind Method; Drug | 1998 |
Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Amino Acids; Arthritis, Rheumatoid; Bone Density; Doub | 1999 |
Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Osteopo | 1999 |
The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.
Topics: Absorptiometry, Photon; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Alkaline Phosphatase; Arth | 1999 |
36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Cohort Studies; Databases, Factual; Etidronic Acid; Female; F | 1999 |
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density; Consumer Product | 2000 |
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Channel Blockers; Double-Bl | 2000 |
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Ca | 2000 |
Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease.
Topics: Adrenal Cortex Hormones; Aged; Connective Tissue Diseases; Drug Administration Schedule; Etidronic A | 2000 |
Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial.
Topics: Adult; Aged; Biomarkers; Bone Density; Bone Remodeling; Calcium; Collagen; Collagen Type I; Drug The | 2000 |
Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation.
Topics: Adrenal Cortex Hormones; Adult; Calcitriol; Calcium; Cyclosporine; Etidronic Acid; Female; Fractures | 2001 |
Management of male osteoporosis.
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Dietary Supplements; Etidronic Acid; Femu | 2001 |
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2001 |
Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Femur Neck; Glucocorticoids; Hip; Huma | 2001 |
COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy.
Topics: Absorptiometry, Photon; Binding Sites; Bone Density; Collagen; Collagen Type I; Collagen Type I, alp | 2002 |
Effect of etidronate disodium on bone turnover following surgical menopause.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Calcium-Binding Proteins; Etidronic Acid; Female; Hum | 1989 |
263 other studies available for etidronate and Osteoporosis
| Article | Year |
|---|---|
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal; Etidronic Acid; Fish | 2021 |
History of etidronate.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; History, 20t | 2020 |
Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, Am J Med. 2004;117:549-555.
Topics: Calcitonin; Etidronic Acid; Female; Hormone Replacement Therapy; Humans; Hydroxycholecalciferols; Os | 2020 |
Concerns About the Integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: The Reply.
Topics: Calcitonin; Etidronic Acid; Female; Hormone Replacement Therapy; Humans; Hydroxycholecalciferols; Os | 2020 |
From osteoporosis to pseudoxanthoma elasticum - etidronate in a vascular disease.
Topics: Etidronic Acid; Humans; Osteoporosis; Pseudoxanthoma Elasticum; Vascular Calcification; Vascular Dis | 2020 |
Phosphate functionalized (4,4)-armchair CNTs as novel drug delivery systems for alendronate and etidronate anti-osteoporosis drugs.
Topics: Alendronate; Drug Carriers; Drug Delivery Systems; Durapatite; Etidronic Acid; Osteoporosis; Phospha | 2017 |
Teriparatide vs risedronate for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Teriparatide vs risedronate for osteoporosis - Authors' reply.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Diphosphonates; Etidronic Acid; Female; | 2019 |
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2019 |
Persistence with osteoporosis medication among newly-treated osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Huma | 2013 |
Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cost of Illness; Database | 2013 |
Is there a role for combination therapy for osteoporosis?
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid; Terip | 2013 |
Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
Topics: Adsorption; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Chemistry, Pharmaceutica | 2013 |
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Topics: Aged; Alendronate; Barrett Esophagus; Bone Density Conservation Agents; Case-Control Studies; Diphos | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Dis | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidr | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; | 2014 |
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats.
Topics: Animals; Bone Density; Bone Resorption; Collagen; Etidronic Acid; Femur; Free Radical Scavengers; Gl | 2014 |
Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Et | 2014 |
Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chol | 2014 |
Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorb | 2015 |
Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Neurofibromatos | 2015 |
Breast cancer. Risedronate reduces bone loss.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Nitriles; Osteoporos | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
Bone: Will breast cancer chemoprevention stand on 'solid bone'?
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Nitriles; Osteoporos | 2015 |
[Osteodeficiency in chronic pancreatitis: ways of correction].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Bone Density Conservation | 2014 |
Risedronate as an intra-abdominal sepsis mimic: a case report.
Topics: Abdominal Abscess; Aged; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Ac | 2015 |
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; | 2008 |
Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Computer Simulation; Etidronic Acid; Female; Humans; | 2008 |
Osteoporosis in men.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Osteoporosis; | 2008 |
Monthly risedronate (Actonel) for postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Fees, Pharmaceutical | 2008 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone | 2009 |
[Severe oesophagus injury as a complication during treatment with risedronic acid].
Topics: Aged; Bone Density Conservation Agents; Esophagus; Etidronic Acid; Gastrointestinal Motility; Humans | 2008 |
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model | 2008 |
Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Syne | 2008 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2009 |
Biomechanical analysis of combined treatment of high calcium and bisphosphonate in tibia of steroid-treated growing-phase rats.
Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Ag | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
[Differences among bisfosfonates--specificity of risedronate (Actonel)].
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Fractures, Spontaneo | 2008 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; F | 2009 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic A | 2009 |
[Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis].
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservatio | 2009 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Drug Administration Schedule; Drug Evaluatio | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidroni | 2010 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fem | 2009 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo | 2009 |
Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocortico | 2009 |
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clo | 2009 |
Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
Topics: Apolipoproteins; Arteries; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; Et | 2009 |
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Etidronic Acid; Female; | 2009 |
Risedronic acid: new indication. No fewer symptomatic fractures in men.
Topics: Clinical Trials as Topic; Drug Approval; Etidronic Acid; Fractures, Bone; France; Humans; Male; Oste | 2008 |
Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Cell Su | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2009 |
Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Etidronic Acid; Female; Mice; Mice, Inbre | 2010 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2010 |
Gastric and esophagus events before and during treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Causality; Clodroni | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2010 |
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Surv | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonate | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
Stroke in relation to use of raloxifene and other drugs against osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmar | 2011 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Hum | 2010 |
Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Fractures, | 2011 |
Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dental Arch; Dental Prosthesis, I | 2012 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.
Topics: Afferent Pathways; Animals; Back Pain; Bone Density Conservation Agents; Cells, Cultured; Disease Mo | 2010 |
How to prevent glucocorticoid-induced osteoporosis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Humans; Organometallic Compounds; | 2010 |
Osteoporosis medication and reduced mortality risk in elderly women and men.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; | 2011 |
Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome.
Topics: Adult; Back Pain; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Etidronic A | 2012 |
Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats.
Topics: Anatomy, Cross-Sectional; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Etid | 2011 |
Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alph | 2011 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Multiple vertebral compression fractures associated with post partum osteoporosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fractures, C | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Remodeling; Case-Control Studies; Diphosphonates; | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the | 2012 |
Effect of stopping risedronate after long-term treatment on bone turnover.
Topics: Aged; Bone Density; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur; Humans; Lumbar V | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diph | 2011 |
Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model.
Topics: Administration, Topical; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fe | 2012 |
Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Topics: Aged; Alendronate; Atherosclerosis; Bone Density Conservation Agents; Calcium; Cohort Studies; Dipho | 2012 |
The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drugs, Gener | 2012 |
Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agen | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; F | 2011 |
Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Topics: Administration, Oral; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation A | 2013 |
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity; | 2012 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; E | 2012 |
Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Density; Calcitriol; Etidronic Acid; Female; Ost | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibilit | 2001 |
[The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Bone Density; Collagen Dise | 2002 |
Commentary on: Bone mineral density and fracture prevalence in long-term kidney graft recipients.
Topics: Bone Density; Etidronic Acid; Fractures, Bone; Humans; Kidney Transplantation; Osteoporosis; Prevale | 2002 |
Once-a-week risedronate (actonel).
Topics: Administration, Oral; Digestive System; Diphosphonates; Dose-Response Relationship, Drug; Drug Admin | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Topics: Adult; Aged; Alendronate; Bone Density; Calcium; Cost-Benefit Analysis; Estrogen Replacement Therapy | 2003 |
[Psychiatric side effects associated with diphosphonate treatment].
Topics: Adult; Attention; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Male; M | 2003 |
Tolerability and compliance with risedronate in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointe | 2003 |
[Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
Topics: Alendronate; Budgets; Drug Costs; Etidronic Acid; Evidence-Based Medicine; Germany; Humans; National | 2003 |
Show us the numbers.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Drug Industry; Etidronic Acid; Humans; Incidence | 2003 |
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.
Topics: Aged; Alendronate; Analysis of Variance; Canada; Diphosphonates; Drug Therapy, Combination; Etidroni | 2003 |
Spectrophotometric determination of some drugs for osteoporosis.
Topics: Alendronate; Etidronic Acid; Osteoporosis; Risedronic Acid; Spectrophotometry | 2003 |
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Calcification, Physiologic; Carbonates; Collage | 2003 |
Long-term effect of intermittent cyclical etidronate on microarchitecture and quality of trabecular bone in an elderly woman with severe osteoporosis.
Topics: Aged; Aged, 80 and over; Biopsy; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; | 2004 |
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Etidronic Acid; Female; Humans; Kynurenine; Methotrexat | 2003 |
Prevention of trabecular bone loss in the mandible of ovariectomized rats.
Topics: Animals; Bone Density; Calcitonin; Calcium, Dietary; Estriol; Etidronic Acid; Female; Germanium; Man | 2004 |
[Consistent therapeutic success in osteoporosis].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2004 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic | 2004 |
New treatments for brittle bones.
Topics: Alendronate; Animals; Bone Density; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
[Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].
Topics: Age Factors; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Hip F | 2004 |
Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?
Topics: Aged; Alendronate; Canada; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Prejudic | 2004 |
Sophie's bones: a case study in osteoporosis.
Topics: Aged; Etidronic Acid; Female; Humans; Osteoporosis; Radiography | 2004 |
Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers.
Topics: Adult; Age Factors; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium, Dietary; Estrogens | 2005 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou | 2004 |
Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Femur; Hip Fractures; Humans; Hydroxycholecal | 2005 |
Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Diphosphonates; Dogs; Drug Resistance; Etidronic | 2005 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; | 2004 |
A case of post-pregnancy osteoporosis-related spinal fractures in association with ankylosing spondylitis.
Topics: Adult; Bed Rest; Calcitonin; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; F | 2005 |
[Asthma--prevention of glucocorticoid-induced osteoporosis with etidronate and calcium].
Topics: Asthma; Calcium; Etidronic Acid; Glucocorticoids; Humans; Osteoporosis | 2005 |
Fracture prevalence and treatment with bone-sparing agents: are there urban-rural differences? A population based study in Ontario, Canada.
Topics: Aged; Aged, 80 and over; Calcium; Canada; Dietary Supplements; Estrogens; Etidronic Acid; Female; Fr | 2005 |
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?
Topics: Aged; Aging; Bone Density; Drug Prescriptions; Etidronic Acid; Female; Fractures, Bone; Hip Fracture | 2005 |
Potential impact of osteoporosis treatment on hip fracture trends.
Topics: Aged; Bone and Bones; Bone Density; Canada; Clinical Trials as Topic; Etidronic Acid; Female; Hip Fr | 2005 |
Risedronate induced BOOP complicated with sarcoidosis.
Topics: Aged; Calcium Channel Blockers; Cryptogenic Organizing Pneumonia; Etidronic Acid; Female; Humans; Mu | 2005 |
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
Topics: Alendronate; Body Height; Body Weight; Bone Density; Bone Density Conservation Agents; Etidronic Aci | 2006 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2005 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Hospitalization-related bone loss and the protective effect of risedronate.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur | 2006 |
A bright future for osteoporosis treatment.
Topics: Adrenergic beta-Antagonists; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2005 |
High-throughput in vivo screening for bone anabolic compounds with zebrafish.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Cholecalcife | 2005 |
[Risedronate: a possible treatment for extraosseous calcification].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; CREST Syndrome; Etidronic | 2005 |
[Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middl | 2005 |
Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
Symptomatic hypocalcemia due to oral risedronate therapy.
Topics: Adult; Bone Density Conservation Agents; Celiac Disease; Etidronic Acid; Humans; Hypocalcemia; Male; | 2005 |
The article of Torregrosa JV et al. is virtually identical to the previous publication of Arlen DJ et al.
Topics: Bone Density; Etidronic Acid; Humans; Kidney Transplantation; Osteoporosis | 2005 |
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Topics: Alendronate; Databases as Topic; Diphosphonates; Drug Prescriptions; Drug Utilization; Etidronic Aci | 2006 |
Is the increase in osteoporosis prevention a result of the audit?
Topics: Adrenal Cortex Hormones; Alendronate; Bone Density Conservation Agents; Calcium; Clinical Trials as | 2006 |
Osteoporosis in older people: a tale of two studies (and three treatments).
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hum | 2006 |
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Glucocorticoids; | 2006 |
[Only bone densitometry answers this question. How stable are your patients' bones?].
Topics: Absorptiometry, Photon; Aged; Bone Density; Diphosphonates; Etidronic Acid; Femoral Neck Fractures; | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Ma | 2006 |
Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium, Dietary; Dietary Supplements; Dr | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation | 2006 |
[Management of corticosteroid-induced osteoporosis].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Calcium; Cortisone; Dip | 2006 |
Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts.
Topics: Absorptiometry, Photon; Acid Phosphatase; Alendronate; Animals; Arthritis, Experimental; Bone Densit | 2006 |
Prevention and treatment of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cost-Benefit Analysis; Diphosphonates; Etidr | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidron | 2007 |
[Men also need bone protection].
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2006 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
Importance of negative trials.
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Inflammatory Bowel Diseases; Osteoporosis; | 2007 |
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Logistic Model | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis | 2007 |
[Osteoporosis treatment: choices and options].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Aci | 2007 |
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Mo | 2007 |
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Bone; Humans; Jap | 2008 |
[Patient's preference for the daily and weekly bisphosphonate--evaluation from questionnaire of osteoporosis patients].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administratio | 2008 |
[Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].
Topics: Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Risedronic Acid | 2008 |
[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].
Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fracture | 2008 |
[On efficiency of local xidiphone in treating osteoporotic changes in hands of vibration disease patients].
Topics: Administration, Topical; Bone Density; Bone Density Conservation Agents; Electrophoresis; Etidronic | 2007 |
What is new in the treatment of steroid-induced osteoporosis?
Topics: Bone Density Conservation Agents; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Human | 2007 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidr | 2008 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Cons | 2008 |
[Sodium etidronate (EHDP) and osteoporosis].
Topics: Adult; Aged; Bone Resorption; Calcium; Cyclic AMP; Etidronic Acid; Female; Humans; Hydroxyproline; M | 1981 |
Diphosphonates in the evaluation of metabolic bone disease.
Topics: Bone and Bones; Bone Diseases, Metabolic; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosph | 1982 |
Osteoporosis, osteomalacia, rickets, and Paget's disease.
Topics: Anti-Inflammatory Agents; Calcitonin; Calcium; Diet; Estrogens; Etidronic Acid; Humans; Osteitis Def | 1984 |
Skeletal calcium homeostasis and countermeasures to prevent disuse osteoporosis.
Topics: Adult; Bed Rest; Bone and Bones; Bone Development; Bone Resorption; Calcitonin; Calcium; Etidronic A | 1984 |
Preliminary observations of a form of coherence therapy for osteoporosis.
Topics: Aged; Biopsy; Bone and Bones; Drug Evaluation; Drug Therapy, Combination; Etidronic Acid; Female; Hu | 1984 |
Toxic epidermal necrolysis, pancytopenia and adult respiratory syndrome.
Topics: Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Pancytopenia; Respiratory Distress Syndro | 1995 |
Etidronate in the management of glucocorticoid-induced osteoporosis.
Topics: Bone Remodeling; Etidronic Acid; Glucocorticoids; Humans; Osteoporosis | 1995 |
From the Congressional Office of Technology Assessment.
Topics: Etidronic Acid; Government Agencies; Humans; Information Services; Mass Media; Osteoporosis; Private | 1995 |
How to assess drug efficacy in osteoporosis.
Topics: Bone Density; Calcitonin; Drug Approval; Estrogens; Etidronic Acid; Fractures, Bone; Humans; Osteopo | 1995 |
Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
Topics: Bone Density; Calcium; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis | 1994 |
Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia.
Topics: Aged; Anemia, Pernicious; Drug Therapy, Combination; Etidronic Acid; Follow-Up Studies; Humans; Male | 1994 |
Osteoporotic vertebral collapse in a woman.
Topics: Aged; Back Pain; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Osteoporosis; Spinal | 1994 |
[The option of etidronate in the treatment of osteoporosis].
Topics: Bone Density; Etidronic Acid; Humans; Osteoporosis | 1993 |
Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and messenger ribonucleic acid markers of osteoblast and osteoclast function.
Topics: Animals; Biomarkers; Bone Density; Etidronic Acid; Femur; Male; Osteoblasts; Osteoclasts; Osteoporos | 1993 |
Fracture risk in woman with osteoporosis: must tennis cease?
Topics: Aged; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Risk Factors; Tennis | 1993 |
Bone histomorphometry.
Topics: Bone and Bones; Bone Remodeling; Endocrine System Diseases; Estrogens; Etidronic Acid; Humans; Osteo | 1993 |
Effects of etidronate and oophorectomy on the zeta potential of rat bone.
Topics: Animals; Bone and Bones; Etidronic Acid; Female; Male; Membrane Potentials; Osteoporosis; Ovariectom | 1996 |
[Systemic mastocytosis as a cause of osteoporosis].
Topics: Absorptiometry, Photon; Adult; Calcium Carbonate; Etidronic Acid; Humans; Imidazoles; Male; Mastocyt | 1996 |
Calcium and vitamin D therapy in corticosteroid bone loss: what is the evidence.
Topics: Adrenal Cortex Hormones; Calcitonin; Calcitriol; Calcium; Etidronic Acid; Humans; Osteoporosis; Vita | 1996 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Treatment with etidronate for men with idiopathic osteoporosis.
Topics: Calcium; Etidronic Acid; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies | 1997 |
Preventing glucocorticoid-induced osteoporosis.
Topics: Bone Density; Calcium Carbonate; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; | 1997 |
Evolving toward a new paradigm for prevention of osteoporosis--the time is upon us.
Topics: Alendronate; Diphosphonates; Double-Blind Method; Endocrinology; Estrogens; Etidronic Acid; Humans; | 1997 |
Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; Calcium Citrate; Dose-Response R | 1997 |
[Bisphosphonate therapy in corticoid-induced osteoporosis].
Topics: Adrenal Cortex Hormones; Calcium; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Ac | 1997 |
Intermittent etidronate and corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Male; Osteoporosis; | 1997 |
Intermittent on/off prostaglandin E2 and risedronate are equally anabolic as daily PGE2 alone treatment in cortical bone of ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcium Channel Blockers; Dinoprostone; Drug | 1997 |
Upper gastrointestinal adverse events and cyclical etidronate.
Topics: Aged; Bone Density; Case-Control Studies; Digestive System; Drug Administration Schedule; Etidronic | 1997 |
Pharmaceuticals and osteoporosis.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis | 1998 |
Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases.
Topics: Adult; Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Glucocorticoids; Human | 1998 |
Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro.
Topics: Animals; Arteries; Calcium Channel Blockers; Clodronic Acid; Diphosphonates; Drug Synergism; Etidron | 1998 |
Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Topics: Absorptiometry, Photon; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Calcium; | 1998 |
Standards in advertising. Has Didronel PMO been proved to protect against osteoporosis?
Topics: Drug Industry; Etidronic Acid; Female; Humans; Male; Osteoporosis | 1999 |
Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Bone Density; Bone Remodeling; Calcium; Electron Probe Micro | 1999 |
Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Remodeling; Disease Models, Animal; Drug Administration Schedule; Etid | 1999 |
Risedronic acid. NE 58095, risedronate sodium, Actonel.
Topics: Aged; Animals; Drugs, Investigational; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Os | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis | 1999 |
The time of day that etidronate is ingested does not influence its therapeutic effect in osteoporosis.
Topics: Administration, Oral; Aged; Bone Density; Circadian Rhythm; Drug Administration Schedule; Eating; Et | 2000 |
Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Densitometry; Endocrinology; Etidronic Acid; Female; Ho | 2000 |
A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Calcitonin; Canad | 2000 |
Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease.
Topics: Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthralgia; Diphosphonates; Etidronic Acid; Fo | 2000 |
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates | 2000 |
[A new bisphosphonate. A vertebral body fracture seldom remains alone].
Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal | 2000 |
New developments in osteoporosis treatment.
Topics: Alendronate; Anticholesteremic Agents; Drug Administration Schedule; Etidronic Acid; Humans; Osteopo | 2000 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; | 2000 |
Bone mineral density in the long term after liver transplantation.
Topics: Absorptiometry, Photon; Adolescent; Adult; Anti-Inflammatory Agents; Antimetabolites; Azathioprine; | 2000 |
Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Bone Density; Cohort Studies; Etidronic Acid; Female; Humans; Male; Mi | 2000 |
Ulcerative esophagitis caused by etidronate.
Topics: Aged; Esophageal Diseases; Esophagitis; Etidronic Acid; Female; Humans; Osteoporosis; Ulcer | 2001 |
Hip fractures: do preventive drugs work for all?
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Os | 2001 |
Treatment of established bone loss after renal transplantation with etidronate.
Topics: Adult; Bone Density; Cohort Studies; Etidronic Acid; Female; Femur; Fractures, Bone; Humans; Kidney | 2001 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diph | 2001 |
Osteoporosis in men.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid | 2001 |
Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs.
Topics: Adult; Aged; Alendronate; Calcitonin; California; Drug Prescriptions; Drug Utilization Review; Etidr | 2001 |
Etidronic acid and steroid therapy: new indication. No proven impact on fractures.
Topics: Calcium; Clinical Trials as Topic; Drug Therapy, Combination; Etidronic Acid; Female; Fluorides; Fra | 1999 |
[Fluorides and bisphosphonates in the treatment of osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
Prevention of space flight induced soft tissue calcification and disuse osteoporosis.
Topics: Bed Rest; Bone and Bones; Bone Demineralization, Pathologic; Calcinosis; Calcium; Clodronic Acid; Et | 1993 |
Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Remodeling; Disease Models, Animal | 2001 |
Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats.
Topics: Age Factors; Amino Acids; Animals; Body Weight; Bone Density; Bone Resorption; Denervation; Etidroni | 2002 |
Physicians' liability and drug formulary restrictions.
Topics: Canada; Cost Control; Delivery of Health Care; Etidronic Acid; Female; Humans; Informed Consent; Jur | 2002 |
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Topics: Aged; Calcium Channel Blockers; Cortisone; Costs and Cost Analysis; Double-Blind Method; Etidronic A | 2002 |
Lymphoplasmacytoid lymphoma presenting as severe osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Etidronic Acid; Humans; Leukemia, Lymphocytic, C | 2002 |
[When osteoporosis first manifests itself. Without therapy the next fracture threatens].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2002 |
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone and Bones; Bone Density; Climacteric; Disease Mod | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; | 2002 |
[The hypocalcemia test, using human and salmon synthetic calcitonins. Paradoxical hypercalcemic responses. Responses in patients with Paget's disease treated with EHDP].
Topics: Calcitonin; Calcium; Dose-Response Relationship, Drug; Etidronic Acid; Hormones; Humans; Hyperparath | 1979 |
Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease.
Topics: Adult; Aged; Bone and Bones; Bone Resorption; Calcium; Etidronic Acid; Female; Histocytochemistry; H | 1977 |
Etidronate disodium in postmenopausal osteoporosis.
Topics: Aged; Calcium; Etidronic Acid; Female; Humans; Intestinal Absorption; Kinetics; Menopause; Middle Ag | 1976 |
Retention of etidronate in human, dog, and rat.
Topics: Adult; Animals; Bone and Bones; Dogs; Etidronic Acid; Female; Humans; Male; Osteoporosis; Rats; Rats | 1992 |
[Bone histomorphometric study in involuted fractured osteoporosis treated with 1-ethane-1-hydroxybiphosphonate (etidronate) during one year].
Topics: Aged; Biopsy; Bone and Bones; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spont | 1991 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Bone Density; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopa | 1991 |
Effect of HEBP (1-hydroxyethylidene-1,1-bisphosphonate) on experimental osteoporosis induced by ovariectomy in rats.
Topics: Animals; Body Weight; Calcification, Physiologic; Calcium; Disease Models, Animal; Drug Administrati | 1991 |
Diphosphonates in the treatment of osteoporosis.
Topics: Etidronic Acid; Humans; Osteoporosis | 1990 |
Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study.
Topics: Administration, Oral; Aged; Bone and Bones; Drug Administration Schedule; Etidronic Acid; Female; Hu | 1989 |
Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Drug Administration Schedule; Drug Therapy | 1989 |
[Inhibition of prednisolone osteopathy by diphosphonate (EHDP) in an animal experiment].
Topics: Animals; Bone and Bones; Cricetinae; Etidronic Acid; Male; Mesocricetus; Osteoporosis; Prednisolone | 1989 |
Morphological analysis of iliac crest bone biopsies in patients with osteoporosis and treatment according to the ADFR concept with (1-38)hPTH and diphosphonate (EHDP)--Osteoporosis Study I, Hannover.
Topics: Biopsy; Drug Therapy, Combination; Etidronic Acid; Humans; Ilium; Osteoclasts; Osteoporosis; Parathy | 1989 |
Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Diphosphonates; Disease Models, Animal; Estrogens | 1989 |
Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans.
Topics: Adult; Bone Resorption; Cell Count; Etidronic Acid; Humans; Immobilization; Male; Osteoclasts; Osteo | 1989 |
Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Resorption; Calcium Carbonate; Drug Therapy, Co | 1988 |
Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.
Topics: Adult; Bone and Bones; Clinical Protocols; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteop | 1988 |
Effects of diphosphonate on osteoporosis induced in rats. Roentogenological, histological and biomechanical studies.
Topics: Animals; Body Weight; Bone and Bones; Calcium, Dietary; Castration; Denervation; Drug Administration | 1985 |
Treatment of Paget's disease of bone.
Topics: Animals; Bone Resorption; Calcitonin; Dactinomycin; Etidronic Acid; Glucagon; Humans; Osteitis Defor | 1973 |
The role of diphosphonates in osteoporosis of disuse.
Topics: Animals; Body Weight; Bone and Bones; Calcitonin; Calcium; Calcium Radioisotopes; Etidronic Acid; Fe | 1973 |